[ { "id": "alphafold", "name": "AlphaFold", "company": "Google", "region": "global", "tagline": "DeepMind's protein structure prediction model", "description": "AlphaFold predicts protein structures and, from AlphaFold 3, the structures of complexes involving proteins, nucleic acids and small molecules. Numbered releases are generations of one model rather than separate products. It is distributed through the AlphaFold Protein Structure Database and the AlphaFold Server for non-commercial research.", "users": "2M+ researchers", "userCount": 2000000, "releaseDate": "2020-11", "technicalImpact": 84, "competitors": [ "Aidoc", "Viz.ai", "RapidAI", "Riverain", "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Protein structure prediction", "200M+ predicted structures", "Open database", "Free API", "Suite modules: AlphaFold 3", "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity" ], "pricing": { "free": "Open access to AlphaFold DB" }, "link": "https://alphafold.ebi.ac.uk", "apiLink": "https://alphafold.ebi.ac.uk/api-docs", "aiCoreShare": 82, "scoringRationale": "DeepMind's protein structure prediction model has been used by 2M+ researchers and predicted structures for 200M+ proteins across nearly all known sequences. Score reflects genuine scientific-field transformation — AlphaFold eliminated a 50-year grand challenge in biology and is now a standard tool in drug discovery, enzyme engineering, and academic research. Kept at 84 rather than higher because it is a scientific research tool rather than a commercial platform with revenue lock-in.", "versions": [ { "name": "AlphaFold 3", "released": "2024-05", "variants": [ "Protein–ligand complexes", "Nucleic acid interactions", "AlphaFold Server" ] }, { "name": "AlphaFold 2", "released": "2021-07", "note": "Protein structure prediction; basis of the AlphaFold Protein Structure Database." } ], "sourceUrls": [ "https://alphafoldserver.com/about", "https://deepmind.google/science/alphafold/" ], "versionsUpdated": "2026-07-29" }, { "id": "lunit-scope", "name": "Lunit SCOPE", "company": "Lunit", "region": "korea", "tagline": "", "description": "Lunit SCOPE is Lunit's precision-oncology AI platform for pathology and biomarker analysis. It has global biopharma relevance, but product-level customer counts are not publicly disclosed.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Lunit discloses global partnerships and the Guardant360 TissueNext PD-L1 test powered by Lunit SCOPE PD-L1, but does not disclose a customer count for SCOPE.", "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.lunit.io/en/precision-oncology/", "apiLink": null, "aiCoreShare": 85, "scoringRationale": "Precision-oncology biomarker analysis with pharmaceutical partner evidence. userCount: 0; no disclosed patient, institutional, or revenue scale. Lowered from 80 to 76: early commercial stage clinical AI; regulatory clearance and partner relationships are defensibility signals, not impact signals.", "sourceUrls": [ "https://www.lunit.io/en/precision-oncology/", "https://www.lunit.io/en/company" ], "contentReview": "needs-review" }, { "id": "gpt-rosalind", "name": "GPT-Rosalind", "company": "OpenAI", "region": "global", "tagline": "Life-sciences research model for biology and drug-discovery workflows", "description": "GPT-Rosalind is OpenAI's purpose-built life-sciences research model for qualified enterprise research teams. It supports biological reasoning, target discovery, genomics interpretation, pathway analysis, literature synthesis, hypothesis generation, and tool-heavy early discovery workflows.", "users": "Research preview for qualified enterprise customers", "userCount": 0, "releaseDate": "2026-04", "technicalImpact": 79, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Biological reasoning", "Target discovery", "Genomics interpretation", "Literature synthesis", "Scientific tool use", "Enterprise access controls" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://openai.com/index/introducing-gpt-rosalind/", "apiLink": "https://platform.openai.com", "aiCoreShare": 91, "adoptionSignal": "OpenAI says GPT-Rosalind is available as a research preview for qualified enterprise customers through trusted access; product-user counts are not disclosed.", "scoringRationale": "GPT-Rosalind is OpenAI's life-sciences research model for protein, drug, and genomics research workflows — distinct from ChatGPT's general medical Q&A. Reduced from 82 to 79: at 82 it exceeded Lunit SCOPE (80), which has credible clinical partner evidence and precision-oncology workflow depth. Rosalind has 0 disclosed research institution users and competes in a space where AlphaFold (84, 2M researchers) and Insilico Medicine tools have stronger domain-specific adoption evidence. 79 reflects genuine life-sciences positioning above general-purpose models but below specialized tools with demonstrated research deployment.", "sourceUrls": [ "https://openai.com/index/introducing-gpt-rosalind/", "https://help.openai.com/en/articles/20001193-introducing-gpt-rosalind-for-life-sciences-research" ] }, { "id": "dragon-copilot", "name": "Dragon Copilot", "company": "Microsoft", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://microsoft.com/health", "apiLink": null, "aiCoreShare": 73, "contentReview": "needs-review" }, { "id": "nuance-clinical-documentation-ai", "name": "Nuance Clinical Documentation AI", "company": "Microsoft", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://microsoft.com/health", "apiLink": null, "aiCoreShare": 83, "contentReview": "needs-review" }, { "id": "med-palm", "name": "Med-PaLM", "company": "Google DeepMind", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://sites.research.google/gr/med-palm/", "apiLink": null, "aiCoreShare": 84, "sourceUrls": [ "https://sites.research.google/gr/med-palm/" ], "contentReview": "needs-review" }, { "id": "dax-copilot", "name": "DAX Copilot", "company": "Microsoft", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://microsoft.com/health", "apiLink": null, "aiCoreShare": 73, "contentReview": "needs-review" }, { "id": "microsoft-cloud-for-healthcare-ai", "name": "Microsoft Cloud for Healthcare AI", "company": "Microsoft", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://microsoft.com/health", "apiLink": null, "aiCoreShare": 77, "scoringRationale": "Microsoft Cloud for Healthcare is the HIPAA-compliant Azure platform bundle for healthcare organizations, integrating Azure OpenAI, Teams, Power Platform, and Dynamics 365 for clinical and administrative AI workflows. 78 reflects Microsoft's enterprise distribution and regulatory compliance infrastructure; kept at 78 because the product is a cloud platform bundle rather than a specialized clinical AI with independent clinical evidence.", "contentReview": "needs-review" }, { "id": "aview-cac", "name": "AVIEW CAC", "company": "Coreline Soft", "region": "korea", "tagline": "Coronary artery calcium scoring from CT", "description": "AVIEW CAC is Coreline Soft's automated coronary artery calcium scoring tool, quantifying calcification from chest CT to stratify cardiovascular risk, used inside hospital screening workflows and Korean national screening programmes. Coreline Soft is KOSDAQ-listed; per-product scan volumes are not disclosed.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "lunit-insight", "vuno-med", "qtrack", "gleamer-copilot", "aidoc-aios" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.corelinesoft.com/en/solutions/cac", "apiLink": null, "aiCoreShare": 78, "sourceUrls": [ "https://www.corelinesoft.com/en/solutions/cac" ], "scoringRationale": "Coreline Soft AVIEW CAC is an FDA-cleared AI tool for automated coronary artery calcium scoring from non-contrast CT, enabling cardiovascular risk stratification without cardiologist manual measurement. 78 reflects FDA clearance, a specific regulated clinical use case, and hospital workflow integration; kept at 78 because deployment scale is not publicly disclosed." }, { "id": "aview-lung-texture", "name": "AVIEW Lung Texture", "company": "Coreline Soft", "region": "korea", "tagline": "Quantitative lung texture analysis on CT", "description": "AVIEW Lung Texture is Coreline Soft's quantitative CT analysis for interstitial lung disease and emphysema, measuring tissue patterns that support diagnosis and longitudinal follow-up. It runs in the same hospital imaging workflow as the rest of the AVIEW suite. Scan volumes are not disclosed.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "lunit-insight", "vuno-med", "qtrack", "gleamer-copilot", "aidoc-aios" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.corelinesoft.com/en/solutions/lung-texture", "apiLink": null, "aiCoreShare": 90, "sourceUrls": [ "https://www.corelinesoft.com/en/solutions/lung-texture" ], "scoringRationale": "Coreline Soft AVIEW Lung Texture is an FDA-cleared AI tool for automated lung texture analysis and fibrosis pattern classification from CT, supporting pulmonologist diagnosis workflows. 78 reflects FDA clearance and a specific regulated clinical indication; kept at 78 because commercial deployment scale is not separately disclosed." }, { "id": "corti-quality-assurance", "name": "Corti Quality Assurance", "company": "Corti", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://corti.ai", "apiLink": null, "aiCoreShare": 93, "scoringRationale": "Corti Quality Assurance reviews emergency call recordings against clinical protocols using AI, surfacing missed questions, protocol deviations, and coaching opportunities for dispatch centers — without requiring real-time use. 78 reflects a real clinical quality product with emergency-service deployments; kept at 78 because it is a back-office QA layer rather than a front-line clinical decision tool like Corti Triage.", "contentReview": "needs-review" }, { "id": "lunit-insight", "name": "Lunit INSIGHT", "company": "Lunit", "region": "korea", "tagline": "AI-powered cancer detection", "description": "Lunit INSIGHT is Lunit's AI radiology platform for cancer detection, spanning mammography, DBT, and chest X-ray workflows with FDA-cleared components and real international deployment.", "descriptionKo": "Lunit INSIGHT는 루닛의 AI 방사선 판독 플랫폼으로, 유방촬영술(MMG), 디지털 단층합성술(DBT), 흉부 X-선(CXR) 분석 기능을 하나로 묶은 암 진단 솔루션입니다. 65개국 이상 의료기관 1만 곳 이상에 실제 배포되어 있으며, FDA 인허가를 받은 컴포넌트를 갖추고 PACS·뷰어와 연동됩니다. 미국에서는 Akumin, Rezolut, SimonMed Imaging, UC Davis Health가 고객사로 이름을 올리고 있습니다. 유방 촬영 1백만 건 돌파(미국 기준) 및 글로벌 방사선과 워크플로우 내 실질적인 임상 적용이 공개된 점에서, 한국 헬스케어 AI 제품 중 가장 넓은 글로벌 배포 증거를 갖추고 있습니다.", "users": "10,000+ customer sites", "userCount": 10000, "adoptionSignal": "Lunit reports 10,000+ medical institutions or customer sites across 65+ countries. Named U.S. providers include Akumin, Rezolut, SimonMed Imaging, and UC Davis Health.", "releaseDate": "2018-01", "technicalImpact": 82, "competitors": [ "vuno-med", "Aidoc", "Viz.ai", "RapidAI", "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Chest X-ray analysis", "Mammography and tomosynthesis analysis", "Regulatory-cleared radiology workflow", "PACS/viewer integration", "Suite modules: Lunit INSIGHT DBT, Lunit INSIGHT MMG, Lunit INSIGHT CXR" ], "pricing": { "enterprise": "Contact Lunit for healthcare pricing" }, "link": "https://www.lunit.io/en/ai-radiology-software/", "apiLink": "https://www.lunit.io/en/ai-radiology-software/", "aiCoreShare": 83, "scoringRationale": "10,000+ customer sites is real institutional deployment. Lowered from 86 to 82 to apply domain-blind scoring: FDA clearance is a defensibility signal, not an impact multiplier. At equivalent site-count evidence in finance or education, products score 78-82. Lunit INSIGHT earns 82 for global hospital penetration across multiple cancer-imaging modalities, but the score is anchored to institutional sites, not patient volume.", "sourceUrls": [ "https://www.lunit.io/", "https://www.lunit.io/en/company/news/akumin-selects-lunit-insight-dbt-to-enhance-nationwide-breast-imaging-services", "https://www.lunit.io/en/company/news/lunit-surpasses-1-million-mammograms-in-us-one-year-after-volpara-acquisition", "https://www.lunit.io/en/media-hub/lunit-nets-fda-nod-for-ai-powered-3d-breast-tomosynthesis-solution-lunit-insight-dbt/", "https://www.lunit.io/en/company/news/lunits-ai-software-for-breast-cancer-detection-lunit-insight-mmg-wins-fda-clearance" ] }, { "id": "heidi-ai-scribe", "name": "Heidi AI Scribe", "company": "Heidi Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://heidihealth.com", "apiLink": null, "aiCoreShare": 79, "scoringRationale": "Heidi AI Scribe is a real-time ambient AI scribe that listens to doctor-patient consultations and generates structured clinical notes, referrals, and letters. Used by 50K+ clinicians in Australia and expanding internationally. 78 reflects real clinical workflow embedding and meaningful disclosed user base; kept at 78 because ChatGPT and general LLMs can perform clinical note generation with similar quality, and the moat rests on EHR integration and user habit rather than a proprietary clinical AI model.", "contentReview": "needs-review" }, { "id": "viz-ai-one", "name": "Viz.ai One", "company": "Viz.ai", "region": "global", "tagline": "Care-coordination platform for time-critical imaging findings", "description": "Viz.ai One detects time-critical findings on CT — large-vessel occlusion, pulmonary embolism, cardiac conditions — and alerts the specialist directly on mobile, compressing the coordination delay between scan and treatment. Hospitals buy the platform; the clinical modules run on it.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 79, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Viz LVO, Viz Cardio Suite, Viz PE" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://viz.ai", "apiLink": null, "aiCoreShare": 87, "scoringRationale": "Viz.ai One is the unified Viz.ai platform that consolidates AI-powered care coordination across cardiovascular, neurology, and pulmonology specialties — routing alerts, connecting care teams, and tracking time-sensitive cases. 78 reflects a real hospital platform product with multi-specialty deployment; kept at 78 because it is a coordination layer above the individual cleared algorithms (Viz LVO, Viz Cardio) rather than a standalone cleared AI.", "sourceUrls": [], "versions": [ { "name": "Viz.ai One", "variants": [ "Viz LVO", "Viz Cardio Suite", "Viz PE" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "generate-platform", "name": "Generate Platform", "company": "Generate Biomedicines", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://generatebiomedicines.com", "apiLink": null, "aiCoreShare": 83, "contentReview": "needs-review" }, { "id": "qtrack", "name": "qTrack", "company": "Qure.ai", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.qure.ai/product/qtrack", "apiLink": null, "aiCoreShare": 81, "sourceUrls": [ "https://www.qure.ai/product/qtrack" ], "contentReview": "needs-review" }, { "id": "aview-copd", "name": "AVIEW COPD", "company": "Coreline Soft", "region": "korea", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.corelinesoft.com/en/solutions/copd", "apiLink": null, "aiCoreShare": 87, "sourceUrls": [ "https://www.corelinesoft.com/en/solutions/copd" ], "contentReview": "needs-review" }, { "id": "exscientia-ai-design", "name": "Exscientia AI Design", "company": "Exscientia", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://exscientia.ai", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "chemistry42", "name": "Chemistry42", "company": "Insilico Medicine", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://insilico.com/chemistry42/", "apiLink": null, "aiCoreShare": 91, "sourceUrls": [ "https://insilico.com/chemistry42/" ], "contentReview": "needs-review" }, { "id": "aview-lcs", "name": "AVIEW LCS", "company": "Coreline Soft", "region": "korea", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.corelinesoft.com/en/solutions/lcs", "apiLink": null, "aiCoreShare": 82, "sourceUrls": [ "https://www.corelinesoft.com/en/solutions/lcs" ], "contentReview": "needs-review" }, { "id": "freed-soap-notes", "name": "Freed SOAP Notes", "company": "Freed", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://freed.ai", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "aisight", "name": "AISight", "company": "PathAI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.pathai.com/ap-lab-solutions", "apiLink": null, "aiCoreShare": 91, "sourceUrls": [ "https://www.pathai.com/ap-lab-solutions" ], "contentReview": "needs-review" }, { "id": "gleamer-copilot", "name": "Gleamer Copilot", "company": "Gleamer", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://gleamer.ai", "apiLink": null, "aiCoreShare": 82, "contentReview": "needs-review" }, { "id": "polaris-constellation", "name": "Polaris Constellation", "company": "Hippocratic AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://hippocraticai.com/polaris/", "apiLink": null, "aiCoreShare": 93, "sourceUrls": [ "https://hippocraticai.com/polaris/" ], "contentReview": "needs-review" }, { "id": "rad-ai-reporting", "name": "Rad AI Reporting", "company": "Rad AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://radai.com", "apiLink": null, "aiCoreShare": 92, "contentReview": "needs-review" }, { "id": "noom-med-ai", "name": "Noom Med AI", "company": "Noom", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 72, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://noom.com", "apiLink": null, "aiCoreShare": 85, "scoringRationale": "Noom Med AI is the AI companion for Noom's prescription weight-loss program, supporting patients on GLP-1 medications with lifestyle coaching and check-ins. Reduced from 76 to 72: the AI layer is a general health coaching chatbot — ChatGPT and Claude can provide equivalent support. The prescription and medical supervision components are the real moat, not the AI. 0 AI-specific user counts disclosed. 72 reflects a real product embedded in a regulated prescription workflow but with minimal AI differentiation.", "contentReview": "needs-review" }, { "id": "vuno-med", "name": "VUNO Med", "company": "Vuno", "region": "korea", "tagline": "AI diagnostics for medical imaging", "description": "VUNO Med is Vuno's regulated medical-AI suite across chest X-ray, retinal imaging, and DeepCARS cardiac-arrest risk prediction. Public product pages support MFDS/CE evidence and FDA breakthrough or clearance evidence by module, but product-specific deployment counts are not disclosed in the catalog.", "users": "Not disclosed", "userCount": 0, "releaseDate": "2017-01", "technicalImpact": 79, "competitors": [ "lunit-insight", "Aidoc", "Viz.ai", "RapidAI", "Riverain", "Insitro", "Recursion", "Atomwise", "BenevolentAI", "Dascena InSight" ], "features": [ "Medical imaging and biosignal AI", "Chest X-ray, bone age, fundus, and DeepCARS modules", "Hospital workflow integration", "MFDS, CE, FDA, or breakthrough-device evidence where module-specific", "Suite modules: VUNO Med-Chest X-ray, VUNO Med-BoneAge, VUNO Med-DeepCARS, VUNO Med-Fundus AI" ], "pricing": { "enterprise": "Contact Vuno for healthcare pricing" }, "link": "https://www.vuno.co/en/chest", "apiLink": "https://www.vuno.co/en", "aiCoreShare": 93, "scoringRationale": "High-quality regulated Korean medical-AI suite with MFDS/CE depth and hospital workflow integration. No disclosed patient scale or revenue. Lowered from 84 to 79 (previously from 87→84 for same reason): FDA/MFDS clearance is a Protected/defensibility signal, not an Impact multiplier. 79 reflects strong clinical AI with proven hospital workflow depth but no verifiable adoption scale.", "sourceUrls": [ "https://www.vuno.co/en/chest", "https://www.vuno.co/en/fundus", "https://www.vuno.co/en/deepcars", "https://www.vuno.co/en" ] }, { "id": "corti-triage", "name": "Corti Triage", "company": "Corti", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 79, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://corti.ai", "apiLink": null, "aiCoreShare": 85, "scoringRationale": "Corti Triage is an AI-powered emergency dispatch and triage assistant that listens to emergency calls in real time, suggests protocols, and flags high-acuity cases like cardiac arrest during the call — deployed by emergency services in multiple EU countries and the US. 79 reflects a regulated clinical workflow product with real emergency-service deployments and genuine patient-outcome evidence; kept below 80 because specific deployment counts and outcome studies are not disclosed in the catalog.", "contentReview": "needs-review" }, { "id": "openevidence", "name": "OpenEvidence", "company": "OpenEvidence", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://openevidence.com", "apiLink": null, "aiCoreShare": 84, "scoringRationale": "OpenEvidence is a clinical evidence search tool for physicians that answers medical questions with citations from FDA labels, clinical trials, and peer-reviewed literature — purpose-built for clinical decision support. Reduced from 79 to 76: Perplexity and ChatGPT with web access now provide citation-grounded medical answers from similar sources at no cost to clinicians. OpenEvidence's curated source quality and physician-specific UX offer some moat, but it does not have regulatory clearance, EHR integration, or workflow lock-in that would clearly differentiate it from general-purpose AI search. 76 reflects a clinician-focused product with source curation value but a thin moat against fast-improving general AI assistants.", "contentReview": "needs-review" }, { "id": "rad-ai-continuity", "name": "Rad AI Continuity", "company": "Rad AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 79, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://radai.com", "apiLink": null, "aiCoreShare": 84, "scoringRationale": "Rad AI Continuity automates radiology follow-up tracking — identifying which patients need imaging follow-up based on radiologist report text, closing a major gap in radiology workflow compliance. Used by health systems to reduce missed follow-ups. 79 reflects a high-value radiology workflow product with real health system deployments addressing a documented patient safety gap; kept below 80 because deployment scale and revenue are not publicly disclosed.", "contentReview": "needs-review" }, { "id": "bonemetrics", "name": "BoneMetrics", "company": "Gleamer", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.gleamer.ai/copilot/bonemetrics", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://www.gleamer.ai/copilot/bonemetrics" ], "scoringRationale": "Gleamer BoneMetrics is an FDA-cleared AI tool for automated bone density and fracture risk assessment from routine CT scans, enabling opportunistic osteoporosis screening without dedicated DXA imaging. 78 reflects FDA clearance and a clinically important opportunistic screening use case; kept at 78 because deployment counts are not disclosed.", "contentReview": "needs-review" }, { "id": "paige-fullfocus", "name": "Paige", "company": "Paige", "region": "global", "tagline": "AI for digital pathology slide review", "description": "Paige analyses whole-slide pathology images to flag suspicious regions for the pathologist, with modules across prostate, breast and general review. It holds FDA clearance for prostate cancer detection — the first for AI in pathology. Deployment counts are not disclosed.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Paige Breast, Paige Alba, Paige Prostate" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://paige.ai", "apiLink": null, "aiCoreShare": 91, "scoringRationale": "Paige FullFocus is Paige's FDA-cleared AI for whole-slide image analysis in prostate pathology, assisting pathologists with cancer detection and grading. Paige holds the first-ever FDA clearance for an AI-powered pathology product. 78 reflects regulatory first-mover advantage and real pathology lab deployment; kept at 78 because deployed case volume and health system customer counts are not publicly disclosed.", "sourceUrls": [], "versions": [ { "name": "Paige", "variants": [ "Paige Breast", "Paige Alba", "Paige Prostate" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "nabla-copilot", "name": "Nabla Copilot", "company": "Nabla", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 77, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://nabla.com", "apiLink": null, "aiCoreShare": 83, "contentReview": "needs-review" }, { "id": "noom-weight-ai", "name": "Noom Weight AI", "company": "Noom", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://noom.com", "apiLink": null, "aiCoreShare": 78, "scoringRationale": "Noom Weight AI provides personalized weight management guidance, meal logging, and behavioral coaching via AI within the Noom app. Reduced from 77 to 73: ChatGPT, Claude, and Gemini can all provide comparable diet, exercise, and weight-loss advice at no cost. Noom's real moat is its behavioral psychology curriculum and app engagement loop, not a proprietary AI model — and no AI-specific user count is disclosed. 73 reflects a real consumer health AI product with some behavioral methodology differentiation but limited moat against general-purpose LLMs.", "contentReview": "needs-review" }, { "id": "heidi-templates", "name": "Heidi Templates", "company": "Heidi Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://heidihealth.com", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "hippocratic-patient-facing-agents", "name": "Hippocratic Patient-Facing Agents", "company": "Hippocratic AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://hippocraticai.com", "apiLink": null, "aiCoreShare": 88, "contentReview": "needs-review" }, { "id": "pathai-diagnostics", "name": "PathAI Diagnostics", "company": "PathAI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://pathai.com", "apiLink": null, "aiCoreShare": 93, "contentReview": "needs-review" }, { "id": "chroma", "name": "Chroma", "company": "Generate Biomedicines", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 75, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://generatebiomedicines.com/chroma", "apiLink": null, "aiCoreShare": 87, "sourceUrls": [ "https://generatebiomedicines.com/chroma" ], "contentReview": "needs-review" }, { "id": "pandaomics", "name": "PandaOmics", "company": "Insilico Medicine", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 75, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://insilico.com/pandaomics/", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://insilico.com/pandaomics/" ], "contentReview": "needs-review" }, { "id": "suki-platform", "name": "Suki Platform", "company": "Suki", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 75, "competitors": [ "dragon-copilot", "dax-copilot", "nuance-clinical-documentation-ai", "nabla-copilot", "freed-ai-scribe" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://suki.ai", "apiLink": null, "aiCoreShare": 85, "contentReview": "needs-review" }, { "id": "freed-ai-scribe", "name": "Freed AI Scribe", "company": "Freed", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 74, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://freed.ai", "apiLink": null, "aiCoreShare": 93, "contentReview": "needs-review" }, { "id": "pathai-trial-solutions", "name": "PathAI Trial Solutions", "company": "PathAI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 74, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://pathai.com", "apiLink": null, "aiCoreShare": 87, "contentReview": "needs-review" }, { "id": "suki-ehr-assistant", "name": "Suki EHR Assistant", "company": "Suki", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 74, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://suki.ai", "apiLink": null, "aiCoreShare": 80, "contentReview": "needs-review" }, { "id": "freed-visit-summary", "name": "Freed Visit Summary", "company": "Freed", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://freed.ai", "apiLink": null, "aiCoreShare": 90, "contentReview": "needs-review" }, { "id": "heidi-ask", "name": "Heidi Ask", "company": "Heidi Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://heidihealth.com", "apiLink": null, "aiCoreShare": 89, "contentReview": "needs-review" }, { "id": "hippocratic-ai-safety-focused-llm", "name": "Hippocratic AI Safety-Focused LLM", "company": "Hippocratic AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://hippocraticai.com", "apiLink": null, "aiCoreShare": 85, "contentReview": "needs-review" }, { "id": "nabla-ehr-integration", "name": "Nabla EHR Integration", "company": "Nabla", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://nabla.com", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "qxr", "name": "qXR", "company": "Qure.ai", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 73, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.qure.ai/product/qxr", "apiLink": null, "aiCoreShare": 85, "sourceUrls": [ "https://www.qure.ai/product/qxr" ], "contentReview": "needs-review" }, { "id": "openevidence-literature-search", "name": "OpenEvidence Literature Search", "company": "OpenEvidence", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 72, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://openevidence.com", "apiLink": null, "aiCoreShare": 88, "contentReview": "needs-review" }, { "id": "inclinico", "name": "InClinico", "company": "Insilico Medicine", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 71, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://insilico.com/inclinico/", "apiLink": null, "aiCoreShare": 82, "sourceUrls": [ "https://insilico.com/inclinico/" ], "contentReview": "needs-review" }, { "id": "nabla-dictation", "name": "Nabla Dictation", "company": "Nabla", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 71, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://nabla.com", "apiLink": null, "aiCoreShare": 92, "contentReview": "needs-review" }, { "id": "openevidence-answers", "name": "OpenEvidence Answers", "company": "OpenEvidence", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 70, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://openevidence.com", "apiLink": null, "aiCoreShare": 83, "contentReview": "needs-review" }, { "id": "glass-clinical-plans", "name": "Glass Clinical Plans", "company": "Glass Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 69, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://glass.health", "apiLink": null, "aiCoreShare": 84, "contentReview": "needs-review" }, { "id": "tempus", "name": "Tempus", "company": "Tempus AI", "region": "global", "tagline": "AI for precision medicine", "description": "Tempus is an AI-enabled precision medicine platform with the largest clinical database for cancer research.", "users": "50% of oncologists in US", "userCount": 0, "releaseDate": "2015-01", "technicalImpact": 69, "competitors": [ "recursion-os", "insitro", "exscientia-ai-design", "tempus-one" ], "features": [ "Genomic sequencing", "Largest cancer database", "AI-driven insights", "Clinical trial matching" ], "pricing": { "clinical": "Contact Tempus for pricing" }, "link": "https://tempus.com", "apiLink": "https://www.tempus.com/for-researchers", "aiCoreShare": 74 }, { "id": "deepscribe-ambient-ai", "name": "DeepScribe Ambient AI", "company": "DeepScribe", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 68, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://deepscribe.ai", "apiLink": null, "aiCoreShare": 88, "contentReview": "needs-review" }, { "id": "owkin-connect", "name": "Owkin Connect", "company": "Owkin", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 68, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://owkin.com", "apiLink": null, "aiCoreShare": 84, "contentReview": "needs-review" }, { "id": "cradle-platform", "name": "Cradle Platform", "company": "Cradle", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 67, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://cradle.bio", "apiLink": null, "aiCoreShare": 92, "contentReview": "needs-review" }, { "id": "glass-differential-diagnosis", "name": "Glass Differential Diagnosis", "company": "Glass Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 67, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://glass.health", "apiLink": null, "aiCoreShare": 87, "contentReview": "needs-review" }, { "id": "owkin-k", "name": "Owkin K", "company": "Owkin", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 67, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://owkin.com", "apiLink": null, "aiCoreShare": 81, "contentReview": "needs-review" }, { "id": "recursion-os", "name": "Recursion", "company": "Recursion", "region": "global", "tagline": "Phenomics-driven drug discovery platform", "description": "Recursion images cells at scale to build phenotypic maps of biological relationships, then searches those maps for compounds that shift disease phenotypes. The proprietary imaging dataset is the asset. Pipeline progress rather than software adoption is the measure.", "users": "Pharma partners", "userCount": 0, "releaseDate": "2016-01", "technicalImpact": 76, "competitors": [ "insitro", "tempus", "exscientia-ai-design", "Atomwise", "BenevolentAI", "Exscientia" ], "features": [ "Automated experiments", "AI-driven target discovery", "Lead optimization", "Partnership programs", "Suite modules: LOWE, Recursion Map, Recursion Phenomics", "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity" ], "pricing": { "partnership": "Partnership and licensing models" }, "link": "https://recursion.com", "apiLink": null, "aiCoreShare": 93, "sourceUrls": [ "https://recursion.com/lowe" ], "versions": [ { "name": "Recursion", "released": "2016-01", "variants": [ "LOWE", "Recursion Map", "Recursion Phenomics" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "suki-assistant", "name": "Suki Assistant", "company": "Suki", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 67, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://suki.ai", "apiLink": null, "aiCoreShare": 72, "contentReview": "needs-review" }, { "id": "abridge", "name": "Abridge", "company": "Abridge", "region": "global", "tagline": "Ambient clinical documentation inside the EHR", "description": "Abridge converts the clinician-patient conversation into a structured note written directly into Epic, extending into coding and revenue-cycle accuracy. Deep EHR embedding rather than transcription quality is the switching cost.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 70, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Abridge Revenue Cycle, Abridge Inside, Abridge Analytics" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://abridge.com", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [], "versions": [ { "name": "Abridge", "variants": [ "Abridge Revenue Cycle", "Abridge Inside", "Abridge Analytics" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "ambience-autoscribe", "name": "Ambience Healthcare", "company": "Ambience Healthcare", "region": "global", "tagline": "Ambient clinical documentation and coding", "description": "Ambience listens to the clinical encounter and produces the note, the visit summary, referral letters and coding suggestions, targeting both physician documentation burden and revenue-cycle accuracy in one pass.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Ambience AutoCDI, Ambience AutoAVS, Ambience AutoRefer" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://ambiencehealthcare.com", "apiLink": null, "aiCoreShare": 91, "sourceUrls": [], "versions": [ { "name": "Ambience Healthcare", "variants": [ "Ambience AutoCDI", "Ambience AutoAVS", "Ambience AutoRefer" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "aidoc-aios", "name": "Aidoc", "company": "Aidoc", "region": "global", "tagline": "Radiology triage platform across clinical specialties", "description": "Aidoc flags acute findings on CT and X-ray — intracranial haemorrhage, pulmonary embolism, aortic conditions — and reprioritises the radiologist worklist, with its aiOS platform hosting both its own and third-party algorithms. One of the most widely FDA-cleared radiology AI portfolios.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 78, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Aidoc Cardiovascular AI, Aidoc Neuro AI, Aidoc BriefCase" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://aidoc.com", "apiLink": null, "aiCoreShare": 91, "sourceUrls": [], "versions": [ { "name": "Aidoc", "variants": [ "Aidoc Cardiovascular AI", "Aidoc Neuro AI", "Aidoc BriefCase" ] } ], "scoringRationale": "Aidoc Cardiovascular AI provides FDA-cleared detection and alerting for aortic aneurysm, pulmonary embolism, and other cardiovascular findings from CT imaging, integrated into radiology workflow via PACS. 78 reflects FDA-cleared multi-indication cardiovascular coverage and hospital radiology integration; kept at 78 because specific deployment volume and outcome data are not publicly disclosed.", "versionsUpdated": "2026-07-29" }, { "id": "corti-assistant", "name": "Corti Assistant", "company": "Corti", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 64, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://corti.ai", "apiLink": null, "aiCoreShare": 78, "contentReview": "needs-review" }, { "id": "generate-biologics-design", "name": "Generate Biologics Design", "company": "Generate Biomedicines", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 64, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://generatebiomedicines.com", "apiLink": null, "aiCoreShare": 84, "contentReview": "needs-review" }, { "id": "boneview", "name": "BoneView", "company": "Gleamer", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 64, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.gleamer.ai/copilot/boneview", "apiLink": null, "aiCoreShare": 80, "sourceUrls": [ "https://www.gleamer.ai/copilot/boneview" ], "contentReview": "needs-review" }, { "id": "chestview", "name": "ChestView", "company": "Gleamer", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 63, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.gleamer.ai/copilot/chestview", "apiLink": null, "aiCoreShare": 83, "sourceUrls": [ "https://www.gleamer.ai/copilot/chestview" ], "contentReview": "needs-review" }, { "id": "qct", "name": "qCT", "company": "Qure.ai", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 63, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.qure.ai/product/lung-nodule-management", "apiLink": null, "aiCoreShare": 82, "sourceUrls": [ "https://www.qure.ai/product/lung-nodule-management" ], "contentReview": "needs-review" }, { "id": "glass-ai", "name": "Glass AI", "company": "Glass Health", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 62, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://glass.health", "apiLink": null, "aiCoreShare": 92, "contentReview": "needs-review" }, { "id": "qer", "name": "qER", "company": "Qure.ai", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 62, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://www.qure.ai/product/qer", "apiLink": null, "aiCoreShare": 86, "sourceUrls": [ "https://www.qure.ai/product/qer" ], "contentReview": "needs-review" }, { "id": "noom-coach-ai", "name": "Noom Coach AI", "company": "Noom", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 61, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://noom.com", "apiLink": null, "aiCoreShare": 88, "contentReview": "needs-review" }, { "id": "rad-ai-impressions", "name": "Rad AI Impressions", "company": "Rad AI", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 60, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://radai.com", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "exscientia-precision-medicine", "name": "Exscientia Precision Medicine", "company": "Exscientia", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 59, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://exscientia.ai", "apiLink": null, "aiCoreShare": 83, "contentReview": "needs-review" }, { "id": "cradle-assistant", "name": "Cradle Assistant", "company": "Cradle", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 58, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://cradle.bio", "apiLink": null, "aiCoreShare": 84, "contentReview": "needs-review" }, { "id": "cradle-protein-design", "name": "Cradle Protein Design", "company": "Cradle", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 58, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://cradle.bio", "apiLink": null, "aiCoreShare": 86, "contentReview": "needs-review" }, { "id": "tempus-one", "name": "Tempus AI", "company": "Tempus", "region": "global", "tagline": "Clinical and molecular data platform for precision oncology", "description": "Tempus sequences tumours and links results to clinical outcomes across a large real-world dataset, surfacing trial matches and care-pathway gaps to oncologists. The linked molecular-clinical corpus is the asset; Tempus is Nasdaq-listed.", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 76, "competitors": [ "dragon-copilot", "dax-copilot", "nuance-clinical-documentation-ai", "nabla-copilot", "freed-ai-scribe", "Insitro", "Recursion", "Atomwise", "BenevolentAI", "tempus" ], "features": [ "Clinical workflow support", "Evidence synthesis", "Regulated deployment", "Diagnostic or care productivity", "Suite modules: Tempus Next, Tempus Lens, Tempus Hub" ], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://tempus.com", "apiLink": null, "aiCoreShare": 91, "sourceUrls": [], "versions": [ { "name": "Tempus AI", "variants": [ "Tempus Next", "Tempus Lens", "Tempus Hub" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "insitro", "name": "insitro", "company": "Insitro", "region": "global", "tagline": "ML-driven drug discovery", "description": "insitro combines machine learning with high-throughput biology to transform drug discovery.", "users": "Pharma partners", "userCount": 0, "releaseDate": "2018-01", "technicalImpact": 57, "competitors": [ "recursion-os", "tempus", "exscientia-ai-design" ], "features": [ "ML-driven target ID", "Disease model generation", "Predictive drug screening", "iPSC-derived models" ], "pricing": { "partnership": "Partnership models" }, "link": "https://insitro.com", "apiLink": null, "aiCoreShare": 71 }, { "id": "deepscribe-customization-studio", "name": "DeepScribe Customization Studio", "company": "DeepScribe", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 55, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://deepscribe.ai", "apiLink": null, "aiCoreShare": 93, "contentReview": "needs-review" }, { "id": "deepscribe-analytics", "name": "DeepScribe Analytics", "company": "DeepScribe", "region": "global", "tagline": "", "description": "", "users": "Not disclosed", "userCount": 0, "releaseDate": "", "technicalImpact": 54, "competitors": [ "Insitro", "Recursion", "Atomwise", "BenevolentAI" ], "features": [], "pricing": { "free": "Varies by plan", "pro": "Subscription or usage-based", "enterprise": "Contact sales" }, "link": "https://deepscribe.ai", "apiLink": null, "aiCoreShare": 79, "contentReview": "needs-review" }, { "id": "aitrics-vitalcare", "name": "VitalCare", "company": "AITRICS", "region": "korea", "tagline": "AI hospital early-warning system for patient deterioration.", "description": "VitalCare is AITRICS' AI early-warning system predicting sepsis, ICU deterioration, and in-hospital mortality from vital signs and EMR data.", "users": "Major Korean tertiary hospitals", "userCount": 0, "adoptionSignal": "Selected for Korea's 2026 AI Voucher Support Program", "technicalImpact": 76, "competitors": [ "Epic Deterioration Index", "Bayesian Health", "Etiometry", "Excel Medical" ], "features": [ "Sepsis prediction", "Deterioration alerts", "EMR integration", "Korean hospital deployments" ], "pricing": { "free": "N/A", "pro": "Per hospital", "enterprise": "Contact sales" }, "link": "https://www.aitrics.com", "apiLink": null, "aiCoreShare": 90 }, { "id": "deep-bio-deepdx-prostate", "name": "DeepDx Prostate", "company": "Deep Bio", "region": "korea", "tagline": "FDA-cleared AI for prostate cancer grading.", "description": "DeepDx Prostate is Deep Bio's FDA-cleared AI for whole-slide pathology.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "US FDA clearance for prostate cancer grading", "technicalImpact": 78, "competitors": [ "paige-fullfocus", "PathAI", "Ibex Medical", "Indica Labs" ], "features": [ "Digital pathology", "Prostate cancer grading", "FDA cleared", "Whole-slide images" ], "pricing": { "free": "N/A", "pro": "Per hospital", "enterprise": "Contact sales" }, "link": "https://deepbio.co.kr", "apiLink": null, "aiCoreShare": 92, "scoringRationale": "Deep Bio DeepDx Prostate is an FDA-cleared AI for prostate cancer detection and grading from digital pathology slides, providing Gleason score assistance in anatomic pathology workflows. 78 reflects FDA clearance and a specific high-clinical-impact use case (prostate cancer Gleason grading); kept at 78 because deployment scale is not publicly disclosed." }, { "id": "deep-bio-deepdx-plasma", "name": "DeepDx Plasma", "company": "Deep Bio", "region": "korea", "tagline": "AI pathology platform extending to additional cancer types.", "description": "DeepDx Plasma is Deep Bio's broader AI pathology platform.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Korean pathology partner labs", "technicalImpact": 70, "competitors": [ "PathAI", "Paige", "Ibex Medical", "Tempus AI" ], "features": [ "Digital pathology", "Multiple cancer types", "Lab workflow", "AI-assisted diagnosis" ], "pricing": { "free": "N/A", "pro": "Per lab", "enterprise": "Contact sales" }, "link": "https://deepbio.co.kr", "apiLink": null, "aiCoreShare": 90 }, { "id": "standigm-ask", "name": "Standigm ASK", "company": "Standigm", "region": "korea", "tagline": "AI drug discovery platform.", "description": "Standigm ASK is the company's end-to-end AI drug discovery platform.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Korean pharma partnerships (SK Chemicals, Hanmi); $68M raised", "technicalImpact": 76, "competitors": [ "Insitro", "BenevolentAI", "Atomwise", "Recursion" ], "features": [ "Target identification", "Lead design", "Drug repurposing" ], "pricing": { "free": "N/A", "pro": "Partnership", "enterprise": "Contact sales" }, "link": "https://www.standigm.com", "apiLink": null, "aiCoreShare": 94 }, { "id": "galux-design", "name": "GaluxDesign", "company": "Galux", "region": "korea", "tagline": "De novo antibody and protein design platform.", "description": "GaluxDesign is Galux's deep-learning de novo antibody and protein design platform.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Series B $29M in 2026; Celltrion / LG Chem / Boehringer Ingelheim partnerships", "technicalImpact": 78, "competitors": [ "Generate Biomedicines", "Exscientia", "Cradle", "Isomorphic Labs" ], "features": [ "De novo antibody design", "Protein design", "Pharma partnerships" ], "pricing": { "free": "N/A", "pro": "Partnership", "enterprise": "Contact sales" }, "link": "https://galux.co.kr", "apiLink": null, "aiCoreShare": 95, "scoringRationale": "Galux AI Design is a Korean medical device AI platform for prosthetics and implant design, using AI to automate CAD model generation from patient imaging for orthopedic and dental surgical planning. 78 reflects a real regulated-medical-device workflow with Korean regulatory evidence; kept at 78 because international deployment scale is limited and patient volume is not disclosed." }, { "id": "pharos-chemiverse", "name": "Chemiverse", "company": "Pharos iBio", "region": "korea", "tagline": "AI drug discovery with 230M+ data entries.", "description": "Chemiverse is Pharos iBio's AI drug discovery platform with PHI-101 in Phase 1.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "KOSDAQ-listed; PHI-101 in Phase 1", "technicalImpact": 72, "competitors": [ "BenevolentAI", "Recursion", "Atomwise", "Standigm" ], "features": [ "Protein structure data", "Chemistry data", "Pipeline candidates" ], "pricing": { "free": "N/A", "pro": "Partnership", "enterprise": "Contact sales" }, "link": "https://www.pharosibio.com", "apiLink": null, "aiCoreShare": 92 }, { "id": "vivid-brain", "name": "VIVID Brain", "company": "Nunaps", "region": "korea", "tagline": "MFDS-approved VR digital therapeutic for stroke.", "description": "VIVID Brain is Nunaps' VR-based digital therapeutic for stroke-induced visual field defects.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Korea's 3rd MFDS-approved DTx", "technicalImpact": 70, "competitors": [ "Akili Interactive", "Pear Therapeutics", "Big Health", "Click Therapeutics" ], "features": [ "VR therapy", "Stroke rehab", "MFDS approved" ], "pricing": { "free": "N/A", "pro": "Per patient", "enterprise": "Per hospital" }, "link": "https://www.nunaps.com/vivid-brain", "apiLink": null, "aiCoreShare": 80, "sourceUrls": [ "https://www.nunaps.com/vivid-brain" ] }, { "id": "welt-sleepq", "name": "SleepQ", "company": "WELT", "region": "korea", "tagline": "MFDS-approved AI digital therapeutic for insomnia.", "description": "SleepQ is WELT's MFDS-approved AI digital therapeutic for chronic insomnia — Korea's 2nd approved DTx.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS + CE certified", "technicalImpact": 70, "competitors": [ "Big Health Sleepio", "Akili", "Pear Therapeutics", "Click Therapeutics" ], "features": [ "Insomnia DTx", "MFDS approved", "CE certified" ], "pricing": { "free": "N/A", "pro": "Per patient", "enterprise": "Per hospital" }, "link": "https://sleepq.ai", "apiLink": null, "aiCoreShare": 82 }, { "id": "welt-agentz", "name": "AgentZ", "company": "WELT", "region": "korea", "tagline": "Health-behavior AI agent recognized at CES 2026.", "description": "AgentZ is WELT's behavior-change AI agent for health.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "2026 CES Innovation Award", "technicalImpact": 66, "competitors": [ "Calm Health", "Headspace Health", "Big Health", "Akili" ], "features": [ "AI health agent", "Behavior change", "Multi-condition" ], "pricing": { "free": "Limited", "pro": "Subscription", "enterprise": "Contact sales" }, "link": "https://sleepq.ai", "apiLink": null, "aiCoreShare": 86 }, { "id": "skylabs-cart-i", "name": "CART-I", "company": "Sky Labs", "region": "korea", "tagline": "Medical-grade ring with deep-learning AFib detection.", "description": "CART-I is Sky Labs' ring-type continuous cardiac monitor with deep-learning AFib detection.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS + CE cleared; Series C $15M", "technicalImpact": 72, "competitors": [ "AliveCor", "iRhythm", "Apple Watch ECG", "Withings ScanWatch" ], "features": [ "Continuous AFib detection", "Ring form factor", "MFDS + CE cleared" ], "pricing": { "free": "N/A", "pro": "Hardware purchase", "enterprise": "Contact sales" }, "link": "https://www.skylabs.io", "apiLink": null, "aiCoreShare": 84 }, { "id": "skylabs-cart-bp", "name": "CART BP", "company": "Sky Labs", "region": "korea", "tagline": "Continuous blood-pressure monitoring ring.", "description": "CART BP is Sky Labs' continuous blood-pressure monitoring ring.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Built on CART-I platform; regulator-cleared", "technicalImpact": 68, "competitors": [ "AliveCor", "Withings ScanWatch", "Aktiia", "Omron HeartGuide" ], "features": [ "Continuous BP", "Wearable ring", "Deep-learning analysis" ], "pricing": { "free": "N/A", "pro": "Hardware purchase", "enterprise": "Contact sales" }, "link": "https://www.skylabs.io", "apiLink": null, "aiCoreShare": 84 }, { "id": "imagoworks-3dme-crown", "name": "3Dme Crown", "company": "Imagoworks", "region": "korea", "tagline": "AI dental crown CAD in the cloud.", "description": "3Dme Crown is Imagoworks' cloud AI dental CAD.", "users": "Dental labs in 110+ countries", "userCount": 0, "adoptionSignal": "Customers in 110+ countries; Series C $15.6M", "technicalImpact": 72, "competitors": [ "Align Technology", "3Shape", "Exocad", "Dental Wings" ], "features": [ "AI dental CAD", "Cloud delivery", "Global lab network" ], "pricing": { "free": "Free trial", "pro": "Per case", "enterprise": "Contact sales" }, "link": "https://dentbird.com", "apiLink": null, "aiCoreShare": 86 }, { "id": "imagoworks-dentbird", "name": "Dentbird", "company": "Imagoworks", "region": "korea", "tagline": "AI orthodontic and implant planning.", "description": "Dentbird extends Imagoworks' AI dental platform.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Imagoworks dental customer base", "technicalImpact": 68, "competitors": [ "Align Technology", "3Shape", "Pearl", "Overjet" ], "features": [ "AI orthodontic planning", "Implant planning", "Cloud" ], "pricing": { "free": "Free trial", "pro": "Per case", "enterprise": "Contact sales" }, "link": "https://dentbird.com", "apiLink": null, "aiCoreShare": 84 }, { "id": "airs-swiftmr", "name": "SwiftMR", "company": "AIRS Medical", "region": "korea", "tagline": "FDA-cleared deep-learning MRI reconstruction.", "description": "SwiftMR is AIRS Medical's deep-learning MRI image reconstruction.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "FDA + MFDS cleared; fastMRI Challenge winner", "technicalImpact": 78, "competitors": [ "Subtle Medical", "GE HealthCare AIR Recon", "Siemens AI-Rad", "Philips SmartSpeed" ], "features": [ "MRI reconstruction", "Scan-time reduction", "FDA cleared" ], "pricing": { "free": "N/A", "pro": "Per hospital", "enterprise": "Contact sales" }, "link": "https://airsmed.com", "apiLink": null, "aiCoreShare": 92, "scoringRationale": "AIRS Medical SwiftMR is an FDA and CE-cleared AI tool for MRI scan acceleration and image enhancement, reducing scan time while maintaining diagnostic quality through AI-based denoising and resolution enhancement. 78 reflects FDA and CE clearance, a technically differentiated imaging acceleration workflow, and hospital integration; kept at 78 because deployment scale and installed base are not publicly disclosed." }, { "id": "neurophet-aqua-ad", "name": "Neurophet AQUA AD", "company": "Neurophet", "region": "korea", "tagline": "AI brain MRI for Alzheimer's diagnostics.", "description": "Neurophet AQUA AD analyzes brain MRI for Alzheimer's diagnosis.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Targeting companion-diagnostic role for Leqembi / Kisunla", "technicalImpact": 74, "competitors": [ "Cortechs.ai", "Combinostics", "icometrix", "Brainomix" ], "features": [ "Brain MRI AI", "Alzheimer's analysis", "Amyloid-therapy companion" ], "pricing": { "free": "N/A", "pro": "Per scan", "enterprise": "Contact sales" }, "link": "https://www.neurophet.com", "apiLink": null, "aiCoreShare": 92 }, { "id": "3billion-rare-disease", "name": "3billion Rare Disease Test", "company": "3billion", "region": "korea", "tagline": "AI rare-disease whole-exome interpretation.", "description": "3billion's rare-disease test uses ML-based variant interpretation on whole-exome sequencing.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "KOSDAQ-listed; Macrogen spin-out", "technicalImpact": 70, "competitors": [ "Invitae", "Genomic Vision", "Illumina AI", "Tempus" ], "features": [ "AI variant interpretation", "Whole-exome sequencing", "Rare disease" ], "pricing": { "free": "N/A", "pro": "Per test", "enterprise": "Contact sales" }, "link": "https://3billion.io", "apiLink": null, "aiCoreShare": 84 }, { "id": "heuron-stroke", "name": "Heuron Stroke Care", "company": "Heuron", "region": "korea", "tagline": "FDA-cleared AI for stroke imaging triage.", "description": "Heuron Stroke Care is the company's FDA-cleared AI for stroke imaging triage.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "FDA cleared; $28M raised", "technicalImpact": 72, "competitors": [ "RapidAI", "Viz.ai", "Aidoc", "Brainomix" ], "features": [ "Stroke imaging AI", "FDA cleared", "Hospital triage" ], "pricing": { "free": "N/A", "pro": "Per hospital", "enterprise": "Contact sales" }, "link": "https://iheuron.com", "apiLink": null, "aiCoreShare": 92 }, { "id": "heartflow-ffrct", "name": "HeartFlow FFRCT Analysis", "company": "HeartFlow", "region": "global", "tagline": "Non-invasive coronary physiology from CT — replaces diagnostic catheterization for stable chest pain.", "description": "HeartFlow FFRCT Analysis uses patient-specific 3D coronary anatomy reconstructed from CT angiography and computational fluid dynamics to compute fractional flow reserve values at every point in the coronary tree — identifying which blockages restrict blood flow and which are anatomically significant but functionally benign. FDA De Novo cleared 2014, ACC/AHA guideline-endorsed, Medicare-reimbursed at ~$1,017/case. 500,000+ patients managed at 1,400+ institutions globally.", "users": "500K+ patients managed", "userCount": 500000, "releaseDate": "2014", "technicalImpact": 82, "competitors": [ "HeartFlow Plaque Analysis", "Siemens Healthineers cFFR", "Canon Medical" ], "features": [ "Fractional flow reserve from CTA", "Patient-specific coronary modeling", "Hemodynamic simulation", "Risk stratification for revascularization" ], "pricing": { "enterprise": "Per-case pricing ~$1,017 Medicare reimbursement" }, "link": "https://www.heartflow.com/solutions/heartflow-ffrct-analysis/", "apiLink": null, "aiCoreShare": 95, "sourceUrls": [ "https://www.heartflow.com/solutions/heartflow-ffrct-analysis/", "https://ir.heartflow.com/" ], "scoringRationale": "2026-07-29 stress test: reduced 86 -> 82. The evidence is the strongest in the healthcare band — $125.8M SEC-audited 2024 product revenue (+44% YoY), 1,400+ institutions, 500K+ patients, FDA De Novo category creation with CPT billing codes — and the disclosed-revenue lane legitimately clears the domain-blind cap. But the row's own declared peer anchor (RapidAI LVO) now scores 80 with 10M+ scans across 2,500+ hospitals, and Brainomix holds 80 at 1.5M+ patients; 86 left HeartFlow six points above peers with far larger clinical volume. 82 places it at the top of the healthcare band alongside Lunit INSIGHT (10,000+ sites) — audited revenue and reimbursement lock-in versus broader site distribution is a fair tie. The De Novo predicate block and CPT codes are defensibility signals and live in Protected, not Impact." }, { "id": "rapid-lvo", "name": "Rapid", "company": "RapidAI", "region": "global", "tagline": "RapidAI's imaging platform for stroke and vascular triage", "description": "Rapid is RapidAI's clinical imaging platform for time-critical vascular care, with modules for large-vessel occlusion, intracranial haemorrhage and pulmonary embolism running on the same deployment inside a hospital's imaging workflow. Hospitals buy the platform, not individual modules.", "users": "10M+ scans across 2,500+ hospitals", "userCount": 0, "releaseDate": "2020", "technicalImpact": 80, "competitors": [ "viz-ai-one", "brainomix-e-stroke", "Aidoc", "harrison-ai-annalise-ctb", "aidoc-aios", "Viz.ai" ], "features": [ "Large vessel occlusion detection from CTA", "Real-time mobile team notification", "Combined ICH+LVO from non-contrast CT", "Multi-site care coordination", "Suite modules: Rapid ICH, Rapid PE", "Intracranial hemorrhage detection", "Real-time neuro team alerting", "CMS NTAP reimbursement", "Pulmonary embolism detection from CTPA", "Automated mobile physician alert", "FDA cleared 2022", "Cross-specialty portfolio integration" ], "pricing": { "enterprise": "Per-scan or subscription enterprise pricing" }, "link": "https://www.rapidai.com", "apiLink": null, "aiCoreShare": 90, "sourceUrls": [ "https://www.rapidai.com/solutions/stroke/", "https://www.rapidai.com/news/rapid-ncct-stroke/", "https://www.rapidai.com/solutions/pulmonary-embolism/" ], "scoringRationale": "10M+ scans and 2,500+ hospitals are RapidAI portfolio-level claims shared across the stroke product line, not product-specific userCount for LVO alone. Lowered from 86 to 80: FDA clearance is a regulatory signal, not an impact multiplier. 80 reflects credible platform-level deployment without conflating RapidAI's aggregate scan volume with this individual product's reach.", "versions": [ { "name": "Rapid", "released": "2020", "variants": [ "Rapid ICH", "Rapid PE" ] } ], "versionsUpdated": "2026-07-29" }, { "id": "lumineticcore", "name": "LumineticsCore", "company": "Digital Diagnostics", "region": "global", "tagline": "The first autonomous FDA-cleared AI diagnostic in any medical specialty — diabetic retinopathy without physician review.", "description": "LumineticsCore (formerly IDx-DR) delivers fully autonomous diabetic retinopathy and diabetic macular edema diagnoses from retinal images without any physician review — a patient in a primary care office can be diagnosed and referred in a single visit. FDA De Novo authorized April 2018 (first autonomous AI diagnostic in US history). CPT code 92229 established with Medicare reimbursement ~$40–47/case. Deployed at Johns Hopkins, Stanford, Mayo Clinic, HCA Healthcare, Banner Health, and LabCorp.", "users": "Deployed across Hopkins, Stanford, Mayo, HCA, LabCorp", "userCount": 0, "releaseDate": "2018", "technicalImpact": 78, "competitors": [ "eyeart", "Google Health", "Notal Vision", "Retinal AI" ], "features": [ "Autonomous diabetic retinopathy diagnosis", "No physician review required", "Point-of-care primary care deployment", "CPT 92229 Medicare billing" ], "pricing": { "enterprise": "Per-exam pricing; Medicare ~$40–47/case" }, "link": "https://www.digitaldiagnostics.com/products/eye-care/lumineticscode/", "apiLink": null, "aiCoreShare": 92, "sourceUrls": [ "https://www.digitaldiagnostics.com/products/eye-care/lumineticscode/", "https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-artificial-intelligence-based-device-detect-certain-diabetes-related-eye" ], "scoringRationale": "FDA De Novo for autonomous diabetic retinopathy diagnosis is a strong regulatory milestone, not a population-scale impact signal. Deployment at Hopkins, Stanford, and Mayo are prestigious but small-volume prestige sites — no disclosed patient count, exam volume, or revenue. Lowered from 85 to 78: named-hospital prestige without adoption scale does not justify scores above the 78 domain-blind cap for regulated AI with userCount: 0." }, { "id": "concentriq-ap-dx", "name": "Concentriq AP-Dx", "company": "Proscia", "region": "global", "tagline": "FDA-cleared digital pathology AI platform for primary cancer diagnosis and pharma drug development.", "description": "Concentriq AP-Dx is Proscia's FDA-cleared (February 2024) AI-powered digital pathology platform that enables primary cancer diagnosis from whole slide images in clinical labs and supports drug development workflows in pharma. Integrates an AI algorithm marketplace (including Ibex, Visiopharm, Owkin), whole slide imaging management, and pathology workflow tools. 12 million whole slide images from 2 million unique patients. 16 of the top 20 pharmaceutical companies use Concentriq. 22,000+ patients diagnosed daily.", "users": "22K+ patients diagnosed daily; 16/20 top pharma", "userCount": 0, "releaseDate": "2024", "technicalImpact": 76, "competitors": [ "paige-fullfocus", "pathai-diagnostics", "Owkin", "Visiopharm" ], "features": [ "FDA-cleared primary cancer diagnosis", "AI algorithm marketplace", "Whole slide image management", "Pharma drug development workflows" ], "pricing": { "enterprise": "Enterprise licensing" }, "link": "https://www.proscia.com/concentriq-ap-dx/", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://www.proscia.com/concentriq-ap-dx/", "https://www.proscia.com/news/proscia-fda-clearance/" ], "scoringRationale": "FDA cleared for primary cancer diagnosis in February 2024 — early commercial stage. userCount: 0; no disclosed deployment scale beyond named-institution prestige. Lowered from 83 to 76: FDA clearance is a regulatory milestone, not a scale signal; early-stage clinical AI should not score in the 80+ tier without verified patient or revenue evidence." }, { "id": "annalise-cxr", "name": "Annalise CXR", "company": "Harrison.ai", "region": "global", "tagline": "12 FDA-cleared findings from a single chest X-ray — pneumothorax, effusion, vertebral fractures, and more.", "description": "Annalise CXR (Harrison.ai) detects 12 FDA-cleared chest X-ray findings simultaneously including pneumothorax, pleural effusion, vertebral compression fractures, and pneumonia — automatically triaging urgent findings for radiologist review. Deployed at 1,000+ sites globally including 40+ NHS Trusts. 7 million patient cases processed. Harrison.ai rebranded from Annalise.ai in October 2025 to reflect expansion beyond radiology.", "users": "7M+ patient cases; 1,000+ sites", "userCount": 0, "releaseDate": "2021", "technicalImpact": 80, "competitors": [ "rapid-lvo", "Aidoc", "qxr", "Gleamer" ], "features": [ "12 simultaneous FDA-cleared CXR findings", "Automated triage and prioritization", "NHS and hospital PACS integration", "Multi-finding coverage vs single-finding competitors" ], "pricing": { "enterprise": "Per-read or subscription enterprise pricing" }, "link": "https://www.harrison.ai/annalise-enterprise/cxr", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://www.harrison.ai/annalise-enterprise/cxr", "https://www.harrison.ai/news/series-c" ], "scoringRationale": "7M+ patient cases and 1,000+ sites is credible disclosed scale — one of the few healthcare AI products with portfolio-level case evidence. Lowered from 83 to 80 to align with domain-blind scoring: equivalent adoption evidence in education (Khanmigo, 2M users: 80) or finance anchors this at 80. 12 FDA clearances for a single chest X-ray pass is a regulatory-breadth signal, not a scale multiplier." }, { "id": "ecg-ai-portfolio", "name": "ECG-AI Suite", "company": "Anumana", "region": "global", "tagline": "Three first-of-kind FDA clearances detecting fatal cardiac conditions invisible to human readers on standard ECG.", "description": "Anumana's ECG-AI Suite includes three first-of-kind FDA clearances: ECG-AI LEF (low ejection fraction, 2023), ECG-AI PH (pulmonary hypertension, March 2026 — first ever), and ECG-AI CA (cardiac amyloidosis, April 2026 — first ever). Each detects a life-threatening cardiac condition that appears normal on standard ECG to human readers. Algorithms validated on 150,000+ patients; 100+ peer-reviewed publications. CMS OPPS Medicare reimbursement effective January 2025. Mayo Clinic spinout with Boston Scientific as investor.", "users": "150K+ patients in validation studies", "userCount": 0, "releaseDate": "2023", "technicalImpact": 78, "competitors": [ "eko-eleft", "AliveCor", "Cardiologs" ], "features": [ "Low ejection fraction detection from ECG", "Pulmonary hypertension detection (first FDA)", "Cardiac amyloidosis detection (first FDA)", "CMS Medicare reimbursement" ], "pricing": { "enterprise": "Per-test pricing; CMS OPPS reimbursed" }, "link": "https://anumana.ai/our-platform/", "apiLink": null, "aiCoreShare": 93, "sourceUrls": [ "https://www.anumana.ai", "https://www.anumana.ai/news" ], "scoringRationale": "First-of-kind FDA clearances for silent AF, low EF, and hypertrophic cardiomyopathy detection are regulatory milestones. However, the 150K+ patients cited are validation-study participants, not deployed users. No commercial deployment scale disclosed. Lowered from 83 to 78: validation evidence ≠ deployment evidence; regulatory-first rationale without adoption data does not clear the 78 cap." }, { "id": "brainomix-e-stroke", "name": "Brainomix 360 e-Stroke", "company": "Brainomix", "region": "global", "tagline": "10 FDA clearances for stroke imaging triage — mandated across all NHS England and Wales stroke centers.", "description": "Brainomix 360 e-Stroke Suite provides AI-powered stroke imaging decision support including e-ASPECTS (infarct scoring), e-CTA (vessel occlusion), e-CTP (perfusion), and e-MRI — generating standardized quantitative assessments to support thrombectomy patient selection in real time. 10 FDA clearances, CE-marked, deployed in 300+ hospitals across 20+ countries. NHS England and Wales mandate deployment at all stroke centers. 1.5M+ patients. Lancet Digital Health study: 450,000+ patients, >50% increase in thrombectomy rates.", "users": "1.5M+ patients; 300+ hospitals", "userCount": 0, "releaseDate": "2018", "technicalImpact": 80, "competitors": [ "rapid-lvo", "viz-ai-one", "RapidAI" ], "features": [ "ASPECTS infarct scoring from CT", "Vessel occlusion detection from CTA", "Perfusion analysis from CTP", "NHS England mandated deployment" ], "pricing": { "enterprise": "Enterprise hospital licensing" }, "link": "https://www.brainomix.com/e-stroke/", "apiLink": null, "aiCoreShare": 90, "sourceUrls": [ "https://www.brainomix.com/e-stroke/", "https://www.thelancet.com/journals/landig/article/PIIS2589-7500(23)00095-7/fulltext" ], "scoringRationale": "NHS-mandated deployment across all England and Wales stroke centers is genuine national-scale evidence — one of the strongest deployment mandates in clinical AI. 1.5M+ patients is credible. Minor reduction from 82 to 80: no disclosed global revenue or international expansion at comparable scale. 80 reflects the NHS mandate as a strong signal while aligning with domain-blind scoring for single-country national deployment." }, { "id": "bayesian-sepsis-ai", "name": "Bayesian Sepsis AI", "company": "Bayesian Health", "region": "global", "tagline": "First FDA-cleared continuous AI sepsis monitoring — 18% lower mortality when clinicians act on alerts.", "description": "Bayesian Health's continuous AI sepsis monitoring system integrates with EHR data streams to generate real-time sepsis risk scores, triggering alerts before clinical deterioration becomes obvious. FDA 510(k) K250680 cleared April 2026 — first-ever FDA clearance for continuous AI sepsis monitoring. Deployed at Cleveland Clinic, Johns Hopkins Health System, University of Rochester, and MemorialCare. Validated across 764,707 patient encounters: 18% lower in-hospital mortality; at MemorialCare: 3.6% absolute mortality reduction, time-to-antibiotics halved, 90% ED adoption.", "users": "764K+ patient encounters in validation", "userCount": 0, "releaseDate": "2026", "technicalImpact": 76, "competitors": [ "Prenosis", "Epic Deterioration Index", "Dascena" ], "features": [ "Continuous (not episodic) sepsis risk scoring", "EHR stream integration", "Real-time clinical alert generation", "FDA 510(k) cleared April 2026" ], "pricing": { "enterprise": "Enterprise health system licensing" }, "link": "https://www.bayesianhealth.com", "apiLink": null, "aiCoreShare": 92, "sourceUrls": [ "https://www.bayesianhealth.com", "https://www.fda.gov/medical-devices/510k-premarket-notification/k250680" ], "scoringRationale": "First-of-kind FDA clearance for continuous AI sepsis monitoring is a regulatory milestone. The 764K patient encounters cited are from validation studies, not commercial deployment. No commercial scale, revenue, or customer count disclosed. Lowered from 81 to 76: validation data ≠ deployment scale; regulatory-first positioning with no adoption evidence does not clear the 78 evidence threshold." }, { "id": "subtlemr", "name": "SubtleMR", "company": "Subtle Medical", "region": "global", "tagline": "FDA-cleared AI reduces MRI scan time by up to 60% while maintaining diagnostic quality.", "description": "SubtleMR is Subtle Medical's FDA-cleared AI (October 2019) that enhances undersampled or accelerated MRI acquisitions to match full-protocol diagnostic quality — enabling hospitals to reduce scan time by up to 60% on existing scanners without new hardware. Deployed on 1,300+ scanners globally at sites including Mount Sinai, RadNet, and Radiology Partners. SubtleSYNTH (FDA-cleared July 2024) generates synthetic STIR images from existing MRI sequences. Scanner-agnostic: compatible with GE, Siemens, Philips, Canon, and Hitachi systems.", "users": "1,300+ scanners globally", "userCount": 0, "releaseDate": "2019", "technicalImpact": 76, "competitors": [ "GE HealthCare", "Siemens Healthineers MR", "Philips MR" ], "features": [ "MRI scan time reduction up to 60%", "Scanner-agnostic compatibility (5 OEMs)", "Synthetic STIR MRI generation (SubtleSYNTH)", "FDA and CE cleared" ], "pricing": { "enterprise": "Per-scan or enterprise site licensing" }, "link": "https://subtlemedical.com/subtlemr/", "apiLink": null, "aiCoreShare": 85, "sourceUrls": [ "https://www.subtlemedical.com/products/" ], "scoringRationale": "1,300 scanner integrations across 5 OEM brands establish workflow switching costs. However, scanner count is infrastructure-layer adoption, not patient-scale impact — no exam volume or patient count is disclosed. Lowered from 80 to 76: OEM integration is a Protected signal; without disclosed patient or exam scale, 76 reflects infrastructure-layer deployment." }, { "id": "eyeart", "name": "EyeArt", "company": "Eyenuk", "region": "global", "tagline": "Autonomous diabetic retinopathy screening cleared for two camera manufacturers — Norway's national AI eye screening system.", "description": "EyeArt is Eyenuk's FDA-cleared autonomous AI diabetic retinopathy screening system — the only one cleared for use with cameras from two different manufacturers (Topcon NW400 added June 2023). CE-marked for three eye diseases (diabetic retinopathy, AMD, and glaucoma) from a single fundus exam. Selected by South-Eastern Norway Regional Health Authority (covering 3.1M people, >50% of Norway) — the world's first national health system deployment of autonomous AI eye screening. 230,000+ patients screened globally.", "users": "230K+ patients screened; Norway national deployment", "userCount": 230000, "releaseDate": "2020", "technicalImpact": 78, "competitors": [ "lumineticcore", "Google Health", "Notal Vision" ], "features": [ "Autonomous DR diagnosis — no physician review", "Two-manufacturer FDA clearance", "CE-marked for DR, AMD, and glaucoma", "National health system deployment (Norway)" ], "pricing": { "enterprise": "Per-exam enterprise or government pricing" }, "link": "https://www.eyenuk.com/eyeart/", "apiLink": null, "aiCoreShare": 90, "sourceUrls": [ "https://www.eyenuk.com/eyeart/", "https://www.eyenuk.com/news/eyenuk-selected-norway/" ], "scoringRationale": "230K patients screened is verified adoption evidence; Norway national screening program is one-country mandated deployment. Minor reduction from 80 to 78: single-country national program with moderate patient scale; multi-camera FDA clearance is a regulatory signal. 78 reflects real but modest deployment, aligned with domain-blind scoring for regulated AI at this evidence level." }, { "id": "virtual-nodule-clinic", "name": "Virtual Nodule Clinic", "company": "Optellum", "region": "global", "tagline": "World's first FDA-cleared radiomics AI for lung cancer risk prediction — CPT-reimbursed at $650/procedure.", "description": "Optellum's Virtual Nodule Clinic generates a radiomics-based malignancy risk score from 3D CT for pulmonary nodules, helping radiologists and pulmonologists stratify which nodules require immediate biopsy vs. watchful waiting. FDA 510(k) K202300 cleared March 2021 — the world's first radiomics-based digital biomarker for lung cancer cleared by FDA. Also CE-MDR, UKCA, and TGA cleared. Patient Discovery AI automatically surfaces patients with nodule reports from EHR text. 250+ clinical sites, 3M+ nodules analyzed. CPT codes 0721T/0722T at ~$650/procedure.", "users": "3M+ nodules analyzed; 250+ clinical sites", "userCount": 0, "releaseDate": "2021", "technicalImpact": 79, "competitors": [ "Aidoc", "Riverain Technologies", "Rad AI" ], "features": [ "Radiomics lung cancer risk scoring", "Patient Discovery AI from EHR text", "CPT-reimbursed ($650/procedure)", "FDA, CE-MDR, UKCA, TGA cleared" ], "pricing": { "enterprise": "Per-procedure; CPT 0721T/0722T at ~$650" }, "link": "https://www.optellum.com/virtual-nodule-clinic/", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://www.optellum.com/virtual-nodule-clinic/", "https://www.fda.gov/medical-devices/510k-premarket-notification/k202300" ], "scoringRationale": "First-mover FDA 510(k) for radiomics-based lung cancer risk prediction — competitors must run equivalent multi-site clinical trials before seeking clearance. CPT codes 0721T/0722T are established with payer coverage at ~$650/procedure. Cost-effectiveness validated at $4,485/life-year gained. Scored at 79: genuine first-mover radiomics regulatory position and established reimbursement. Stays below 82 because commercial deployment (250+ sites) is smaller than stroke/cardiovascular peers and the company is underfunded relative to its TAM." }, { "id": "eko-eleft", "name": "Eko ELEFT", "company": "Eko Health", "region": "global", "tagline": "FDA-cleared AI stethoscope algorithm detecting low ejection fraction — CMS reimbursed at $128.90/use.", "description": "Eko ELEFT is Eko Health's FDA-cleared AI algorithm (March 2024) that detects low ejection fraction — a marker of heart failure — from a 15-second ECG captured via Eko's digital stethoscope, enabling primary care physicians to screen for heart failure without echocardiography. CMS OPPS reimbursement finalized December 2025 at $128.90/use. Part of a portfolio of 4+ FDA clearances including EFAST (first FDA-cleared cardiac foundation model, 2025). 650,000+ Eko devices sold worldwide.", "users": "650K+ devices sold", "userCount": 0, "releaseDate": "2024", "technicalImpact": 79, "competitors": [ "ecg-ai-portfolio", "AliveCor", "Cardiologs" ], "features": [ "Low ejection fraction from 15-second ECG", "AI stethoscope hardware bundle", "CMS OPPS reimbursed ($128.90/use)", "Cardiac foundation model (EFAST)" ], "pricing": { "enterprise": "Per-use; CMS OPPS $128.90" }, "link": "https://www.ekohealth.com", "apiLink": null, "aiCoreShare": 88, "sourceUrls": [ "https://www.ekohealth.com/clinical-evidence" ], "scoringRationale": "Hardware-bundled AI (digital stethoscope + FDA-cleared algorithm) creates durable per-use reimbursement at $128.90/CMS code. 650K+ device installed base is a distribution moat competitors must build from zero. Cardiac foundation model clearance (EFAST) positions Eko for multi-indication expansion. Scored at 79: CMS reimbursement and installed base are strong. Stays below Anumana ECG-AI Suite (83) because Eko's indications overlap more with competitors (Anumana) and the hardware dependency creates OEM-style margin constraints." }, { "id": "heartflow-plaque-analysis", "name": "HeartFlow Plaque Analysis", "company": "HeartFlow", "region": "global", "tagline": "AI coronary plaque vulnerability analysis from CTA — identifies rupture-prone plaques; nationally covered by Aetna and Cigna.", "description": "HeartFlow Plaque Analysis uses AI to characterize coronary plaque composition from CT angiography data — identifying low-attenuation plaque, positive remodeling, and spotty calcification that indicate high rupture risk. Complements FFRCT by adding plaque vulnerability assessment to hemodynamic analysis. FDA 510(k) cleared October 2022; national payer coverage from Aetna and Cigna.", "users": "Not disclosed", "userCount": 0, "technicalImpact": 80, "competitors": [ "heartflow-ffrct", "Siemens Healthineers cFFR", "Cleerly" ], "features": [ "Coronary plaque composition AI", "Vulnerability risk stratification", "FDA 510(k) cleared 2022", "National Aetna and Cigna coverage" ], "pricing": { "enterprise": "Per-case enterprise pricing" }, "link": "https://www.heartflow.com/solutions/heartflow-plaque-analysis/", "aiCoreShare": 92, "sourceUrls": [ "https://www.heartflow.com/solutions/heartflow-plaque-analysis/" ], "scoringRationale": "FDA 510(k) cleared 2022; national payer coverage from Aetna and Cigna is a real clinical workflow signal. Lowered from 84 to 80: extends the FFRCT moat into plaque vulnerability but no product-specific patient count or revenue is disclosed. 80 reflects genuine clinical workflow integration with national reimbursement, without overstating standalone adoption." }, { "id": "annalise-ctb", "name": "Annalise CTB", "company": "Harrison.ai", "region": "global", "tagline": "FDA Breakthrough–designated brain CT AI for hemorrhage and hematoma — Medicare NTAP reimbursed.", "description": "Annalise CTB (Harrison.ai) detects intracranial hemorrhages, subdural and epidural hematomas, and midline shift from non-contrast brain CT, automatically triaging time-critical findings for immediate radiologist review. FDA Breakthrough Device Designation; Medicare NTAP reimbursement. Part of Harrison.ai's 12-clearance portfolio deployed at 1,000+ sites globally.", "users": "1,000+ sites; 7M+ cases across portfolio", "userCount": 0, "technicalImpact": 79, "competitors": [ "rapid-lvo", "brainomix-e-stroke", "Aidoc", "viz-ai-one" ], "features": [ "Intracranial hemorrhage detection", "Subdural and epidural hematoma AI", "FDA Breakthrough Device Designation", "Medicare NTAP reimbursement" ], "pricing": { "enterprise": "Per-read or subscription enterprise pricing" }, "link": "https://www.harrison.ai/annalise-enterprise/ctb", "aiCoreShare": 90, "sourceUrls": [ "https://www.harrison.ai/annalise-enterprise/ctb", "https://www.harrison.ai/news/series-c" ], "scoringRationale": "FDA Breakthrough Device Designation signals clinical urgency recognized by regulators, not deployment scale. 1,000+ sites is a portfolio claim across Annalise's product line. userCount: 0; no product-specific revenue or patient volume disclosed. Lowered from 83 to 79: early-stage head CT AI; Breakthrough Designation is a regulatory signal, not an impact score driver." }, { "id": "brainomix-e-lung", "name": "Brainomix e-Lung", "company": "Brainomix", "region": "global", "tagline": "AI monitoring of pulmonary fibrosis progression from CT — co-primary endpoint in Boehringer Ingelheim Phase 3 trial.", "description": "Brainomix e-Lung quantifies pulmonary fibrosis extent and progression from serial chest CT scans, generating standardized quantitative scores that track treatment response over time. FDA cleared May 2024; CE-marked. Uniquely positioned as a co-primary endpoint measurement tool in a Boehringer Ingelheim Phase 3 clinical trial — embedding the AI into pharma's drug approval pipeline rather than just clinical practice.", "users": "Not disclosed", "userCount": 0, "technicalImpact": 79, "competitors": [ "Subtle Medical", "Thirona", "IMBIO" ], "features": [ "Pulmonary fibrosis quantification from CT", "Serial progression monitoring", "FDA cleared May 2024", "Pharma trial endpoint integration" ], "pricing": { "enterprise": "Enterprise hospital and pharma licensing" }, "link": "https://www.brainomix.com/e-lung/", "aiCoreShare": 88, "sourceUrls": [ "https://www.brainomix.com/e-lung/" ], "scoringRationale": "Pharma trial co-primary endpoint integration (Boehringer Ingelheim Phase 3) is a uniquely durable moat — drug approval timelines lock in the measurement tool for 3–5+ years. FDA cleared May 2024. Scored at 79: strong strategic positioning in pharma pipeline, but clinical deployment scale is early compared to Brainomix's stroke suite and patient volume is not disclosed." }, { "id": "subtlepet", "name": "SubtlePET", "company": "Subtle Medical", "region": "global", "tagline": "FDA-cleared AI enabling 4x faster PET scans at lower radiotracer dose — scanner-agnostic across major OEMs.", "description": "SubtlePET enhances low-dose or abbreviated PET acquisitions to match full-dose diagnostic quality using AI image reconstruction, enabling hospitals to scan patients 4x faster, reduce radiotracer injection doses, or use both benefits simultaneously. FDA cleared December 2018; CE-marked. Scanner-agnostic: compatible with GE, Siemens, Philips, Canon, and United Imaging PET systems.", "users": "Not disclosed", "userCount": 0, "technicalImpact": 79, "competitors": [ "GE HealthCare", "Siemens Healthineers PET", "Philips PET" ], "features": [ "PET scan time reduction up to 4x", "Radiotracer dose reduction", "Scanner-agnostic (5 OEM brands)", "FDA cleared 2018" ], "pricing": { "enterprise": "Per-scan or enterprise site licensing" }, "link": "https://subtlemedical.com/subtlepet/", "aiCoreShare": 85, "sourceUrls": [ "https://www.subtlemedical.com/products/" ], "scoringRationale": "SubtlePET extends Subtle Medical's scanner-agnostic AI enhancement platform into PET, with FDA clearance since 2018 — one of the earliest AI PET enhancement clearances. Scored at 79: real FDA clearance and multi-OEM compatibility, but PET scanner installed base is smaller than MRI and OEM-native enhancement is a growing competitive threat." }, { "id": "clearread-ct", "name": "ClearRead CT", "company": "Riverain Technologies", "region": "global", "tagline": "AI vessel suppression for chest CT improving nodule visibility; opportunistic CAC scoring from routine ungated CTs.", "description": "ClearRead CT applies AI vessel suppression to chest CT images — removing blood vessels from the display to make lung nodules more visible to radiologists. A 2025 FDA clearance adds opportunistic coronary artery calcium (CAC) scoring from routine ungated chest CTs, enabling cardiovascular risk stratification without dedicated cardiac scans. Deployed across 104 VA medical centers and UCHealth's 5 flagship hospitals.", "users": "104 VA sites; UCHealth 5 hospitals", "userCount": 0, "technicalImpact": 79, "competitors": [ "virtual-nodule-clinic", "Aidoc", "Subtle Medical" ], "features": [ "AI vessel suppression for nodule detection", "Opportunistic CAC scoring from routine CT", "FDA cleared; multiple indications", "104 VA medical center deployment" ], "pricing": { "enterprise": "Enterprise site licensing" }, "link": "https://www.riveraintech.com/clearread-ct/", "aiCoreShare": 85, "sourceUrls": [ "https://www.riveraintech.com/clearread-ct/" ], "scoringRationale": "Opportunistic CAC scoring from routine ungated chest CT (FDA-cleared 2025) opens a new population health screening revenue stream — most chest CTs are ungated, giving ClearRead CT access to a much larger scan volume than dedicated cardiac CT. VA contract base (104 sites) provides durable government revenue. Scored at 79: strong differentiation in opportunistic screening but thin capital and limited disclosed commercial scale." }, { "id": "clearread-xray", "name": "ClearRead Xray", "company": "Riverain Technologies", "region": "global", "tagline": "AI bone suppression and line/tube confirmation for chest X-ray — improves subtle lung lesion detection.", "description": "ClearRead Xray applies AI to suppress rib and clavicle overlay from chest X-rays (ClearRead+Bone), confirm endotracheal tube and catheter positions (ClearRead+Confirm), and generate soft-tissue enhanced views — reducing missed findings in emergency and ICU settings. Multiple FDA clearances. Part of Riverain's chest imaging portfolio bundled with ClearRead CT for enterprise customers.", "users": "Not disclosed", "userCount": 0, "technicalImpact": 77, "competitors": [ "Gleamer", "Aidoc", "harrison-ai-annalise-cxr" ], "features": [ "AI rib/clavicle bone suppression", "Line and tube position confirmation", "Soft-tissue view generation", "Multiple FDA clearances" ], "pricing": { "enterprise": "Enterprise site licensing; often bundled with ClearRead CT" }, "link": "https://www.riveraintech.com/clearread-xray/", "aiCoreShare": 82, "sourceUrls": [ "https://www.riveraintech.com/clearread-xray/" ], "scoringRationale": "ClearRead Xray addresses a genuine clinical workflow gap — rib overlap is a leading cause of missed lung lesions on chest X-ray. Multiple FDA clearances for bone suppression and tube confirmation. Scored at 77: real clinical value and FDA clearances, but the chest X-ray AI market is competitive (Gleamer, Aidoc, Harrison.ai all cleared) and Riverain's commercial scale is limited." }, { "id": "dr-noon-cvd", "name": "Dr. Noon CVD", "company": "Mediwhale", "region": "korea", "tagline": "AI cardiovascular disease risk prediction from a single retinal photograph — MFDS cleared, 8-country international deployment.", "description": "Dr. Noon CVD (Reti-CVD) is Mediwhale's AI that analyzes a fundus retinal photograph to generate a 10-year cardiovascular disease risk score, trained on 1.6M retinal images. Unlike dedicated cardiac imaging, it works on existing fundus cameras at any eye clinic or primary care practice. MFDS cleared with private reimbursement code (June 2023), CE Mark Class IIa, and cleared in Australia, Malaysia, Singapore, Indonesia, Thailand, UK, and Italy. 170+ Korean medical institutions as of March 2026. iCare (Revenio Group) integration for global fundus camera distribution.", "users": "170+ Korean hospitals; 8 international markets", "userCount": 0, "technicalImpact": 78, "competitors": [ "eyeart", "lumineticcore", "sky-labs-cardi-o" ], "features": [ "CVD risk from retinal fundus photo", "1.6M retinal image training set", "MFDS + CE Mark + 8-country clearances", "iCare camera OEM integration" ], "pricing": { "enterprise": "Per-exam hospital pricing; private reimbursement code in Korea" }, "link": "https://www.mediwhale.com/drnoon-cvd/", "aiCoreShare": 90, "sourceUrls": [ "https://www.mediwhale.com" ], "scoringRationale": "Dr. Noon CVD is unique in predicting systemic CVD risk from retinal imaging — no competing product holds equivalent clearances across 8 international markets. 170+ Korean hospital deployments from a 2023 clearance is strong early adoption. iCare camera integration creates OEM distribution. Scored at 78: real multi-market regulatory position and growing hospital network. Stays below 80 because CVD risk scoring from fundus photos is a newer clinical modality without large-scale outcomes evidence and FDA clearance is pending." }, { "id": "mpxa-2000", "name": "MPXA", "company": "Medipixel", "region": "korea", "tagline": "FDA-cleared real-time coronary angiography AI — vessel segmentation and lesion quantification in 1–2 seconds.", "description": "Medipixel MPXA-2000 performs real-time AI vessel segmentation and quantitative coronary angiography (QCA) on coronary angiography images, generating lesion measurements in 1–2 seconds to support interventional cardiologists in the cathlab. MFDS cleared 2021; FDA 510(k) K222036 cleared February 2023. Companion product MPFFR-1000 derives FFR from the same angiography images without a pressure wire (AUC 0.949; AIM-FFR trial ongoing). Presented at EuroPCR 2023. US office in Cambridge, MA.", "users": "Seoul Asan Medical Center; EuroPCR 2023 presented", "userCount": 0, "technicalImpact": 77, "competitors": [ "heartflow-ffrct", "Siemens Healthineers", "Philips" ], "features": [ "Real-time coronary QCA in 1–2 seconds", "FDA 510(k) K222036 cleared", "MFDS cleared for MPXA-2000, MPFFR-1000, MPNeuro", "FFR from angiography without pressure wire" ], "pricing": { "enterprise": "Enterprise cathlab licensing" }, "link": "https://medipixel.io/products/medipixelxa/", "aiCoreShare": 88, "sourceUrls": [ "https://medipixel.io", "https://www.fda.gov/medical-devices/510k-premarket-notification/k222036" ], "scoringRationale": "MPXA-2000 is FDA-cleared (K222036) for real-time coronary QCA — a specific interventional cardiology cathlab workflow. MPFFR-1000 (FFR without pressure wire) is the more differentiated product, with MFDS clearance and an ongoing FDA trial. Scored at 77: real FDA clearance and MFDS clearances, but commercial hospital deployment is early-stage (research partnerships, not named commercial contracts). US Cambridge office signals active commercialization." }, { "id": "airead-cxr", "name": "AIRead-CXR", "company": "Soombit.ai", "region": "korea", "tagline": "Korea's first MFDS-approved generative AI radiology report generator — 57 chest X-ray conditions.", "description": "AIRead-CXR is Soombit.ai's AI that generates preliminary radiology reports for chest X-rays covering 57 conditions, using a generative AI architecture trained on ~14 million data points. MFDS-approved April 2, 2026 as a Class 3 SaMD — the first product approved under MFDS's new Guidelines for Generative AI Medical Devices, marking a regulatory milestone for the generative AI medical device category in Korea. Validated at Seoul National University Hospital and Seoul National University Bundang Hospital.", "users": "Pre-commercial (approved April 2026)", "userCount": 0, "technicalImpact": 73, "competitors": [ "coreline-soft", "lunit-scope-cxr", "vuno-med-chest-xray" ], "features": [ "Generative AI radiology report text generation", "57 chest X-ray condition coverage", "MFDS Class 3 SaMD first-in-category approval", "SNUH and SNUBH clinical validation" ], "pricing": { "enterprise": "Hospital licensing (pre-commercial)" }, "link": "https://soombit.ai/product", "aiCoreShare": 88, "sourceUrls": [ "https://soombit.ai" ], "scoringRationale": "AIRead-CXR holds Korea's first MFDS approval for a generative AI medical device — a regulatory category milestone that establishes the pathway for future generative AI SaMD products. Founded by ex-KakaoBrain healthcare AI leadership with Altos Ventures backing. Scored at 73: the generative AI medical device clearance is a real milestone but the product is pre-commercial with no disclosed hospital clients or revenue. Score re-evaluates upward when commercial deployment and patient case volume are disclosed." }, { "id": "sonix-health", "name": "SONIX HEALTH", "company": "Ontact Health", "region": "korea", "tagline": "MFDS and FDA-cleared AI echocardiography analysis — 70%+ reporting time reduction; ~3,000 institutions worldwide.", "description": "SONIX HEALTH is Ontact Health's AI platform for automated echocardiography analysis — covering quantitative measurement (LV dimensions, volumes, EF), qualitative assessment (wall motion, valvular function), diagnostic summary generation, and referral recommendation from a single echo exam. Reduces exam reporting time by over 70%. Clinical accuracy: B-mode 96%, Doppler 99%, M-mode 100%; LV global longitudinal strain correlation ~0.97. MFDS cleared; FDA 510(k) cleared. ~3,000 medical institutions worldwide as of end-2025. May 2026: Samjin Pharmaceutical exclusive Korea distribution MOU.", "users": "~3,000 institutions worldwide (company-stated)", "userCount": 0, "technicalImpact": 76, "competitors": [ "eko-eleft", "ecg-ai-portfolio", "Samsung Medison" ], "features": [ "Full echocardiography AI — measurement, assessment, summary, referral", "MFDS and FDA cleared", "70%+ reporting time reduction", "Samjin Pharmaceutical Korea distribution" ], "pricing": { "enterprise": "Hospital licensing" }, "link": "https://www.ontacthealth.com/kr/solution/sonix_health.php", "aiCoreShare": 90, "sourceUrls": [ "https://ontacthealth.com" ], "scoringRationale": "SONIX HEALTH holds both MFDS and FDA clearance for automated echocardiography — a complex multi-measurement cardiac imaging workflow. ~3,000 institutions worldwide (company-stated, not independently verified) is a large installed base for a 4-year-old Korean medtech company. Samjin Pharmaceutical exclusive distribution adds national commercial channel. Scored at 76: dual regulatory clearance and meaningful institutional claims. Stays below 78 because the 3,000 institution figure is company-stated and specific revenue/contract evidence is not publicly disclosed." }, { "id": "samsung-z20", "name": "Samsung Z20", "company": "Samsung Medison", "region": "korea", "tagline": "FDA-cleared AI OB/GYN ultrasound — identifies 39 standard views, labels 47 structures, reduces keystrokes 94%.", "description": "Samsung Medison Z20 is an AI-powered obstetric and gynecologic ultrasound system with an integrated AI guidance engine that identifies 39 standard anatomical OB views in real time, automatically labels 47 fetal/maternal anatomical structures, and reduces operator keystrokes by 94% versus conventional ultrasound. FDA 510(k) K241971 cleared in 2024. Part of Samsung Medison's broader AI ultrasound portfolio including S-Detect for Breast (CE, 2016) and S-Detect for Thyroid (CE), plus Auto Lung Nodule Detection (FDA, 2021).", "users": "110 countries across Samsung Medison portfolio", "userCount": 0, "technicalImpact": 77, "competitors": [ "GE HealthCare", "Philips", "Siemens Healthineers" ], "features": [ "39 standard OB view identification", "47 anatomical structure auto-labeling", "94% keystroke reduction", "FDA 510(k) K241971 cleared 2024" ], "pricing": { "enterprise": "Medical device enterprise pricing" }, "link": "https://www.samsungmedison.com/global/product/z20", "aiCoreShare": 80, "sourceUrls": [ "https://www.samsungmedison.com/global/product/z20" ], "scoringRationale": "Samsung Z20 has a 2024 FDA clearance for AI OB/GYN ultrasound with specific, measurable workflow improvements (94% keystroke reduction, 39-view identification). Samsung Medison's $865M revenue and 110-country presence provide global distribution. Scored at 77: real FDA clearance and commercially deployed at global scale. Stays below 80 because Samsung Medison competes primarily on hardware against GE, Philips, and Siemens — the AI layer enhances an existing product rather than standing alone as a software AI platform." }, { "id": "osteo-signal", "name": "Osteo Signal", "company": "Promedius", "region": "korea", "tagline": "MFDS-approved AI for osteoporosis screening from routine chest X-rays — addresses 75% undiagnosis rate pre-fracture.", "description": "Promedius Osteo Signal detects osteoporosis risk from routine chest X-rays without a dedicated DXA scan — targeting the ~75% of osteoporosis patients who are undiagnosed before their first fracture. MFDS approved March 2025 (Innovative Medical Device designation November 2024). Cleared in Vietnam and Indonesia. CE submission expected Q1 2026; FDA clearance expected 2026. Validated at Massachusetts General Hospital, Penn State Health, and Seoul National University Hospital. Clinical evidence published in JBMR Plus (Journal of Bone and Mineral Research Plus).", "users": "Pre-commercial internationally (MFDS approved March 2025)", "userCount": 0, "technicalImpact": 73, "competitors": [ "clearread-ct", "bonemetrics", "Riverain Technologies" ], "features": [ "Osteoporosis risk from routine chest X-ray", "MFDS approved March 2025", "MFDS Innovative Medical Device designation", "MGH and Penn State clinical validation" ], "pricing": { "enterprise": "Hospital licensing (Korea launch 2025)" }, "link": "https://promedius.ai/product/osteo", "aiCoreShare": 88, "sourceUrls": [ "https://promedius.ai" ], "scoringRationale": "Osteo Signal addresses a major screening gap — 75% of osteoporosis patients undiagnosed before fracture — using opportunistic screening from existing chest X-rays with no additional scan cost. MFDS approval and Innovative Medical Device designation March 2025 are hard regulatory milestones. MGH and Penn State partnerships validate international clinical evidence. Scored at 73: real regulatory clearance and strong clinical rationale, but commercial deployment is early-stage and international clearances are pending." }, { "id": "deepnoid-deep-neuro", "name": "DEEP:NEURO", "company": "Deepnoid", "region": "korea", "tagline": "AI detection of cerebral aneurysms on brain MRA", "description": "DEEP:NEURO detects saccular unruptured cerebral aneurysms on brain MRA images to assist physician interpretation, integrating into hospital PACS via DICOM with 3D vessel visualization and rupture-risk reporting. It holds MFDS approval 20-467 and a 2023 Innovative Medical Device designation, with clinical validation at Yonsei Severance Hospital. A November 2024 analyst report cited roughly 24 deploying Korean hospitals; deployment scale beyond Korea is unproven.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS approval 20-467 + Innovative Medical Device designation (2023); ~24 Korean hospitals per Nov 2024 Hana Securities report; Yonsei Severance clinical validation", "technicalImpact": 72, "aiCoreShare": 92, "competitors": [ "lunit-insight", "vuno-med", "Aidoc", "Heuron Stroke Suite" ], "features": [ "Aneurysm detection with bounding-box markers on MRA", "3D MIP multi-angle vascular visualization", "Rupture-risk analysis report", "PACS integration via DICOM" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://www.deepnoid.com/products/medical/deep-neuro", "apiLink": null, "sourceUrls": [ "https://www.deepnoid.com/products/medical/deep-neuro", "https://www.hanaw.com/download/research/FileServer/WEB/info/small_cap/2024/11/14/241115_deepnoid.pdf" ], "scoringRationale": "72 reflects MFDS clearance, innovative-device designation, and analyst-reported ~24-hospital Korean deployment for a listed vendor; capped below 78 per the regulated-niche evidence rule because product-specific patient/user counts and international deployment are not disclosed." }, { "id": "deepnoid-m4cxr", "name": "M4CXR", "company": "Deepnoid", "region": "korea", "tagline": "Generative-AI chest X-ray report drafting", "description": "M4CXR is a multimodal-LLM medical device that drafts preliminary chest X-ray radiology reports covering 41 findings in about 2.3 seconds, trained on roughly 10 million chest X-ray records. It is Korea's first generative-AI medical device to receive MFDS Class 3 approval (2026) and an Innovative Medical Device designation (November 2025). Commercial deployment is just beginning, so customer and usage evidence is not yet public.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS Class 3 approval (2026) — Korea's first generative-AI medical device; Innovative Medical Device designation Nov 2025; pre-commercial", "technicalImpact": 73, "aiCoreShare": 95, "competitors": [ "lunit-insight", "Rad AI Omni Reporting", "Annalise.ai", "vuno-med" ], "features": [ "Automated preliminary CXR report generation (41 findings)", "~2.3s average report generation", "Trained on ~10M chest X-ray records", "MFDS Class 3 approved generative-AI device" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://www.deepnoid.com/products/medical/m4cxr", "apiLink": null, "sourceUrls": [ "https://www.deepnoid.com/products/medical/m4cxr", "https://en.sedaily.com/technology/2026/04/12/medical-ai-approvals-surge-25-fold-in-3-years-now" ], "scoringRationale": "73 reflects a first-of-kind Korean regulatory milestone (MFDS Class 3 generative-AI device) with strong technical differentiation; held below 78 per the regulated-niche cap because the product is pre-commercial with no disclosed deployments." }, { "id": "selvy-checkup", "name": "Selvy Checkup", "company": "Selvas AI", "region": "korea", "tagline": "AI disease-risk prediction from health-checkup data", "description": "Selvy Checkup predicts near-term risk of major diseases from routine health-checkup records using RNN-LSTM models trained on Korean national health-examination cohorts, and is sold to insurers, checkup centers, and healthcare services. Named B2B clients on the product page include Samsung Life, Hana Life, and DB Life. It received a non-device regulatory determination; end-user counts are not disclosed.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "~20 named B2B clients on product page incl. Samsung Life, Hana Life, DB Life; CES 2018 Innovation Award", "technicalImpact": 66, "aiCoreShare": 85, "competitors": [ "Lydia AI", "Klarity Health", "AITRICS VC" ], "features": [ "RNN-LSTM disease-risk models", "National health-exam cohort training data", "Missing-data correction for real-world records", "ISO 27001 / ISMS certified" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://www.selvasai.com/checkup", "apiLink": null, "sourceUrls": [ "https://www.selvasai.com/checkup" ], "scoringRationale": "66 reflects a differentiated insurer/checkup-center prediction workflow with named B2B customers on the first-party page; kept modest because usage volume, revenue contribution, and clinical outcomes are not disclosed." }, { "id": "deargen-dr-ug", "name": "Dr.UG", "company": "Deargen", "region": "korea", "tagline": "Sequence-based AI drug discovery platform", "description": "Dr.UG is Deargen's deep-learning drug-discovery platform combining DearTrans genome/transcriptome analysis, DearDTI drug-target interaction prediction, and MolEQ generative molecule optimization across PROTAC, ADC, and small-molecule modalities. It supports Deargen's internal pipeline and joint research with SK Chemical, Handok, and Samsung Medical Center. No platform user or revenue figures are disclosed.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Joint research with SK Chemical, Handok, Samsung Medical Center; Serengen DNA-encoded library partnership", "technicalImpact": 68, "aiCoreShare": 90, "competitors": [ "standigm-ask", "chemistry42", "hits-hyperlab" ], "features": [ "Transformer-based drug-target interaction prediction (DearDTI)", "Genome and biomarker target discovery (DearTrans)", "Generative molecule design and lead optimization (MolEQ)", "PROTAC, ADC, and small-molecule modality support" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://deargen.me/en/technology/", "apiLink": null, "sourceUrls": [ "https://deargen.me/en/technology/", "https://www.businesswire.com/news/home/20220224005528/en/" ], "scoringRationale": "68 reflects an early Korean sequence-based discovery platform with named pharma research partners; held under the regulated-niche cap because there are no disclosed licensees, revenue, or clinical-stage outcomes attributable to the platform." }, { "id": "oncocross-raptor-ai", "name": "RAPTOR AI", "company": "Oncocross", "region": "korea", "tagline": "Transcriptomics-based AI drug repositioning", "description": "RAPTOR AI matches existing drug candidates to new indications from transcriptomic and multi-omics data, interpreting mechanism-of-action and supporting ADC/bispecific/TPD modalities with Asian multi-omics databases. It underpins Oncocross's Daewoong Pharmaceutical partnership and internal pipeline (OC101, OC514), and carried the company to Korea's first AI-drug-development KOSDAQ listing in December 2024. Platform-specific customer counts are not disclosed.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "First Korean AI-drug-development KOSDAQ listing (Dec 2024); Daewoong Pharmaceutical indication-expansion partnership; Korea Pharma tech transfer (2020)", "technicalImpact": 70, "aiCoreShare": 92, "competitors": [ "standigm-ask", "Healx", "BenevolentAI", "deargen-dr-ug" ], "features": [ "Drug-disease matching and indication discovery", "Mechanism-of-action interpretation via multi-omics", "Asian multi-omics reference databases", "ADC, bispecific, and TPD modality analysis" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://www.oncocross.com/en/raptor", "apiLink": null, "sourceUrls": [ "https://www.oncocross.com/en/raptor", "https://www.bioworld.com/articles/715762-ai-cancer-firm-oncocross-debuts-with-60m-ipo-on-kosdaq" ], "scoringRationale": "70 reflects a public-market-validated repositioning platform with named pharma partnerships; capped below 78 because platform revenue, licensee counts, and clinical outcomes attributable to RAPTOR are not yet disclosed." }, { "id": "hits-hyperlab", "name": "HyperLab", "company": "HITS", "region": "korea", "tagline": "Self-serve SaaS AI drug-discovery workbench", "description": "HyperLab is a cloud SaaS platform for drug discovery: ligand-protein binding prediction, structure-based generative molecule design, screening from one million to trillions of compounds, and ADME/T property prediction in one web workflow. HyperLab 2.0 launched in April 2025 with self-serve free trials and Core/Enterprise plans. Subscriber counts are not disclosed, so adoption remains unproven.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Self-serve SaaS with free trial and Core/Enterprise plans; HyperLab 2.0 launched Apr 2025", "technicalImpact": 68, "aiCoreShare": 92, "competitors": [ "Schrödinger LiveDesign", "standigm-ask", "deargen-dr-ug", "chemistry42" ], "features": [ "Hyper Binding drug-protein interaction prediction", "Hyper Design structure-based generative design", "Screening across million-to-trillion compound libraries", "Hyper ADME/T property and toxicity prediction" ], "pricing": { "free": "Free trial", "pro": "Core subscription", "enterprise": "Contact sales" }, "link": "https://hyperlab.ai/en", "apiLink": null, "sourceUrls": [ "https://hyperlab.ai/en", "https://www.bioworld.com/articles/727277-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery" ], "scoringRationale": "68 reflects a differentiated self-serve SaaS wedge into computational drug discovery from a KAIST-founded team; held modest because subscriber, customer, and revenue evidence is not public.", "nativeName": "하이퍼랩" }, { "id": "medicalai-aitia", "name": "AiTiA", "company": "Medical AI", "region": "korea", "tagline": "AI 12-lead ECG screening for hidden cardiac disease", "description": "AiTiA analyzes standard 12-lead ECGs to flag conditions conventional reads miss: AiTiA LVSD outputs the likelihood of left ventricular systolic dysfunction (heart failure) and AiTiA MI screens for acute myocardial infarction. Both are MFDS Class II cleared with Innovative Medical Device designations (No. 29 and No. 45), deployed in Korean health-checkup centers and hospitals. FDA/CE clearance and audited deployment counts are still pending.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS Class II clearances with Innovative Medical Device designations Nos. 29/45; ~40+ Korean medical institutions reported; Korean press reports 300K paid checkup users within three months of checkup-center launch", "technicalImpact": 72, "aiCoreShare": 94, "competitors": [ "Anumana ECG-AI", "eko-eleft", "AliveCor Kardia", "Ultromics EchoGo" ], "features": [ "12-lead ECG deep-learning analysis for LV systolic dysfunction", "Acute myocardial infarction screening (AiTiA MI)", "Health-checkup center screening workflow", "MFDS Class II with innovative-device designations" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://medicalai.com/en/product/aitia_series/", "apiLink": null, "sourceUrls": [ "https://medicalai.com/en/product/aitia_series/", "https://pharm.edaily.co.kr/news/read?newsId=02364886639024056", "https://thevc.kr/medicalai" ], "scoringRationale": "72 reflects dual MFDS clearances, innovative-device designations, and press-reported checkup-center traction; capped below 78 per the regulated-niche rule until first-party audited deployment or usage counts are public.", "nativeName": "에이티아" }, { "id": "kakao-pasta", "name": "PASTA", "company": "Kakao Healthcare", "region": "korea", "tagline": "AI CGM-based blood-glucose management app", "description": "PASTA pairs with continuous glucose monitors (Dexcom G7, i-SENS CareSens Air) for real-time glucose tracking and uses Vision AI to log meals, exercise, insulin, and medication, correlating lifestyle with glucose response. Launched February 2024, it added blood-pressure (Sky Labs ring), weight, and sleep tracking and is expanding to Japan. Google Play shows 500K+ downloads, but active-user counts are not disclosed.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "Google Play 500K+ downloads; Dexcom G7 and i-SENS CareSens Air integrations; Japan expansion underway", "technicalImpact": 72, "aiCoreShare": 88, "competitors": [ "Dexcom Clarity", "Abbott LibreView", "January AI", "Nutrisense" ], "features": [ "Real-time CGM integration (Dexcom G7, CareSens Air)", "Vision AI meal/exercise/medication logging", "Glucose-vs-lifestyle correlation reports", "Blood-pressure, weight, and sleep extensions" ], "pricing": { "free": "Free app", "pro": "N/A", "enterprise": "N/A" }, "link": "https://en.pastahealth.com/", "apiLink": null, "sourceUrls": [ "https://en.pastahealth.com/", "https://play.google.com/store/apps/details?id=com.kakaohealthcare.pasta", "https://kakaohealthcare.com/en/" ], "scoringRationale": "72 reflects a mass-consumer Korean CGM companion with real device integrations and download traction; capped below 78 because Kakao discloses no product-specific active users and downloads are not users.", "nativeName": "파스타" }, { "id": "ark-wisky", "name": "WISKY", "company": "ARK", "region": "korea", "tagline": "Retinal-photo AI screening for chronic-disease complications", "description": "WISKY screens for early complications of chronic disease from a single retinal photograph in 3-5 seconds, flagging glaucoma, age-related macular degeneration, and diabetic retinopathy, with WISKY-CVD/CKD variants for cardiovascular and kidney risk. It holds MFDS Class III approval and an Innovative Medical Device designation and is distributed to Korean public health centers and clinics via Daewoong Pharmaceutical. Korean press reports 700+ facilities supplied and 100K+ cumulative screenings within about a year; these figures are press-reported rather than audited.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "MFDS Class III + Innovative Medical Device designation; Daewoong distribution; press-reported 700+ facilities and 100K+ cumulative screenings; KRW 20B Series A (Mar 2026)", "technicalImpact": 74, "aiCoreShare": 94, "competitors": [ "Mediwhale DrNoon", "Digital Diagnostics IDx-DR", "Eyenuk EyeArt", "Optomed Aurora AEYE" ], "features": [ "Retinal image analysis in 3-5 seconds", "Glaucoma, AMD, and diabetic retinopathy detection", "WISKY-CVD and WISKY-CKD risk variants", "OPTiNA fundus camera companion hardware" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://aiark.io/default/products/01.php", "apiLink": null, "sourceUrls": [ "https://aiark.io/default/products/01.php", "https://en.sedaily.com/news/2026/03/11/ark-raises-14m-for-ai-powered-early-complication-detection", "https://kormedi.com/2796018/" ], "scoringRationale": "74 reflects MFDS Class III clearance, a national public-health-center distribution channel through Daewoong, and press-reported facility counts; capped below 78 per the regulated-niche rule because adoption figures are press-reported, not first-party audited.", "nativeName": "위스키" }, { "id": "nuvilab-ai-food-scanner", "name": "Nuvilab AI Food Scanner", "company": "Nuvilab", "region": "korea", "tagline": "Vision-AI food scanning and dietary analytics", "description": "Nuvilab's scanners identify food type and portion volume at cafeteria serving and return points, producing intake and waste data used to cut food waste, tune production, and structure dietary records. Verticals include Coconut for foodservice operators, YumYumKids for 1,300+ Korean daycare centers, and Nutrition AI for US hospital meal validation under an exclusive ~$1M catering contract (2025). Company-reported totals (1,000+ clients, 100K active users) are unaudited.", "users": "Not disclosed", "userCount": 0, "adoptionSignal": "1,300+ Korean daycare deployments (site-stated); Aramark/Compass/Ourhome-class catering partners; ~$1M exclusive US foodservice contract (2025); Naver D2SF bridge round Mar 2026", "technicalImpact": 70, "aiCoreShare": 85, "competitors": [ "Winnow", "Leanpath", "Orbisk", "Foodvisor" ], "features": [ "Vision-AI food type and portion-volume recognition", "Intake and waste analytics per menu and site", "YumYumKids childcare dietary program", "Clinical meal validation for hospitals" ], "pricing": { "free": "N/A", "pro": "Per deployment", "enterprise": "Contact sales" }, "link": "https://www.nuvilab.com/en/coconut", "apiLink": null, "sourceUrls": [ "https://www.nuvilab.com/en", "https://pulse2.com/nuvilab-ai-nutrition-analytics-startup-raises-series-a-bridge-funding-to-expand-in-north-america/" ], "scoringRationale": "70 reflects deep institutional deployment in Korean childcare/foodservice and a paid US healthcare contract; kept below 78 because client and user totals are company-reported and per-vertical revenue is undisclosed." }, { "id": "infervision-inferread", "name": "InferRead", "nativeName": "推想医疗", "company": "Infervision", "region": "china", "tagline": "AI imaging triage for lung, chest and stroke workflows", "description": "InferRead is Infervision's AI radiology suite for CT and X-ray triage, covering lung nodule detection, chest disease screening and stroke workflows inside hospital PACS. Infervision reports roughly 20,000 lung-cancer screening scans processed daily — the highest disclosed scan volume of any Chinese medical-imaging AI platform — and deployment across 200+ hospitals. It is the closest Chinese equivalent to Lunit INSIGHT and VUNO Med in the Korea comparison.", "features": [ "Lung nodule detection and cancer screening on CT", "Chest X-ray and pneumonia triage", "Stroke and cerebrovascular workflows", "PACS-integrated hospital deployment", "NMPA Class III clearances" ], "pricing": { "enterprise": "Hospital licensing; contact Infervision" }, "link": "https://global.infervision.com/", "apiLink": null, "users": "~20,000 lung-cancer screening scans/day; 200+ hospitals", "userCount": 0, "releaseDate": "2016", "technicalImpact": 82, "aiCoreShare": 90, "competitors": [ "lunit-insight", "vuno-med", "AIdoc", "Annalise.ai", "airdoc-retinal" ], "adoptionSignal": "Infervision reports ~20,000 lung-cancer screening scans processed per day — roughly 7M scans annually — and deployment reaching its 200th hospital. That is population-scale deployment evidence rather than a pilot claim. Paying-customer count and revenue are not disclosed.", "scoringRationale": "82 reflects disclosed population-scale deployment (~20,000 screening scans/day, 200+ hospitals), which clears the regulated-niche evidence cap of 78 the same way Lunit INSIGHT's 10,000 customer sites do — and it is scored level with Lunit deliberately, since the two carry comparable deployment evidence in the same workflow. Below 84 because Infervision's disclosed reach is domestic rather than the multi-country regulatory footprint Lunit holds, and no revenue or paid-customer figure is public.", "sourceUrls": [ "https://global.infervision.com/", "https://www.dotmed.com/news/story/44345" ] }, { "id": "united-imaging-uai", "name": "uAI", "nativeName": "联影智能", "company": "United Imaging", "region": "china", "tagline": "AI layer across United Imaging's scanner and radiotherapy fleet", "description": "uAI is United Imaging's AI platform embedded across its CT, MRI, PET/CT and radiotherapy systems, covering scan acceleration, automatic positioning, image reconstruction and diagnostic assistance. United Imaging accounted for 11% of all AI-based medical devices approved in China between 2020 and 2025 — 17 of 154, the largest share of any single vendor — and its uMR Ultra 3T MRI holds NMPA approval alongside FDA clearance and the CE mark.", "features": [ "AI image reconstruction and scan acceleration", "Automatic patient positioning and protocol selection", "Diagnostic assistance across CT, MRI and PET/CT", "Radiotherapy planning support", "NMPA, FDA and CE regulatory coverage" ], "pricing": { "enterprise": "Bundled with United Imaging systems; contact sales" }, "link": "https://www.united-imaging.com/en/product-service/uai/", "apiLink": null, "users": "Embedded across United Imaging's installed scanner base; unit counts not disclosed", "userCount": 0, "releaseDate": "2017", "technicalImpact": 80, "aiCoreShare": 70, "competitors": [ "Siemens Healthineers AI-Rad", "GE HealthCare Edison", "Philips SmartSpeed", "infervision-inferread" ], "adoptionSignal": "United Imaging holds the largest share of NMPA-approved AI medical devices in China — 17 of 154 approvals between 2020 and 2025 (11%) — and its uMR Ultra carries NMPA, FDA and CE clearance. It is STAR-listed with overseas revenue up 42% year over year in the first three quarters of 2025. Installed-unit counts for the AI layer specifically are not disclosed.", "scoringRationale": "80 reflects the largest AI-device approval share of any vendor in China plus multi-jurisdiction clearance (NMPA, FDA, CE) and listed-company scale with growing overseas revenue. It clears the 78 regulated-niche cap on regulatory breadth and installed-base distribution, but stays below Infervision (82) because approvals and an installed fleet are distribution rather than disclosed AI usage — no scan volume or AI-specific adoption figure is published. `aiCoreShare` is 70 because uAI ships bundled with hardware whose value is largely the scanner itself.", "sourceUrls": [ "https://www.united-imaging.com/en/product-service/uai/", "https://medinform.jmir.org/2026/1/e85538" ] }, { "id": "airdoc-retinal", "name": "Airdoc Retinal AI", "nativeName": "鹰瞳科技", "company": "Airdoc", "region": "china", "tagline": "Retinal image analysis for chronic-disease screening", "description": "Airdoc's retinal AI analyses fundus photographs to screen for diabetic retinopathy, hypertensive retinopathy and other chronic-disease markers, deployed through hospitals, health-check centres, pharmacies and optical chains. Airdoc listed on the Hong Kong Stock Exchange in November 2021 — the first AI medical-imaging listing on HKEX — which is its clearest verifiable milestone; screening volumes are not disclosed.", "features": [ "Fundus image analysis for diabetic and hypertensive retinopathy", "Chronic-disease risk markers from retinal imaging", "Health-check centre and pharmacy deployment", "Portable fundus camera integration", "NMPA Class III clearance" ], "pricing": { "enterprise": "Per-screening or licensing; contact Airdoc" }, "link": "https://www.airdoc.com/en/", "apiLink": null, "users": "Not disclosed", "userCount": 0, "releaseDate": "2015", "technicalImpact": 78, "aiCoreShare": 92, "competitors": [ "mediwhale", "lunit-insight", "infervision-inferread", "Eyenuk", "Digital Diagnostics" ], "adoptionSignal": "Airdoc listed on HKEX in November 2021 as the first AI medical-imaging company on that exchange and holds NMPA Class III clearance for retinal screening. Screening volumes, deployment counts and revenue attribution for the AI product are not disclosed.", "scoringRationale": "78 is the regulated-niche evidence cap: Airdoc is a listed company with Class III clearance and a real screening product, but discloses no screening volume, deployment count or population-scale evidence. It is scored the same way Korean retinal-AI peers with clearance but no disclosed volume are — the cap is applied identically regardless of country. Clears to 82 with disclosed screening volumes or a mandated national programme.", "sourceUrls": [ "https://www.airdoc.com/en/" ] } ]